CA2047742A1 - Method and diagnostic test kit for detection of anti-cardiolipin - Google Patents
Method and diagnostic test kit for detection of anti-cardiolipinInfo
- Publication number
- CA2047742A1 CA2047742A1 CA002047742A CA2047742A CA2047742A1 CA 2047742 A1 CA2047742 A1 CA 2047742A1 CA 002047742 A CA002047742 A CA 002047742A CA 2047742 A CA2047742 A CA 2047742A CA 2047742 A1 CA2047742 A1 CA 2047742A1
- Authority
- CA
- Canada
- Prior art keywords
- cardiolipin
- solution
- antibodies
- wells
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 230000003429 anti-cardiolipin effect Effects 0.000 title claims description 78
- 238000002405 diagnostic procedure Methods 0.000 title claims description 5
- 238000001514 detection method Methods 0.000 title abstract description 18
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 31
- 210000002966 serum Anatomy 0.000 claims description 25
- 238000003556 assay Methods 0.000 claims description 23
- 238000000576 coating method Methods 0.000 claims description 21
- 239000011248 coating agent Substances 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 14
- 230000009871 nonspecific binding Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims 2
- 238000002965 ELISA Methods 0.000 abstract description 17
- 238000003018 immunoassay Methods 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000013096 assay test Methods 0.000 abstract 1
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 62
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 34
- 238000012360 testing method Methods 0.000 description 34
- 239000000523 sample Substances 0.000 description 25
- 239000003085 diluting agent Substances 0.000 description 21
- 239000000758 substrate Substances 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 14
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000005018 casein Substances 0.000 description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 13
- 235000021240 caseins Nutrition 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000012888 bovine serum Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 5
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000006379 syphilis Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229940075894 denatured ethanol Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001046 green dye Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940124272 protein stabilizer Drugs 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 101001043817 Homo sapiens Interleukin-31 receptor subunit alpha Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 101001076857 Pisum sativum Ribulose bisphosphate carboxylase small subunit, chloroplastic 2 Proteins 0.000 description 1
- 206010064620 Placental infarction Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- LEOJDCQCOZOLTQ-UHFFFAOYSA-N dibutylcarbamothioyl n,n-dibutylcarbamodithioate Chemical compound CCCCN(CCCC)C(=S)SC(=S)N(CCCC)CCCC LEOJDCQCOZOLTQ-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000045410 human IL31RA Human genes 0.000 description 1
- 102000053880 human mitochondria proteolipid-like Human genes 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 231100001046 intrauterine death Toxicity 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method and apparatus optimized as a diagnostic sandwich assay test kit, which has immobilized cardiolipins onto a precoated support surface utilized for the purpose of detection of antibodies specific to such compounds by either ELISA (Enzyme Linked Immunosorbent Assay) or FIA (Fluorescent Immunoassay) techniques.
Description
-1- 20~77~2 M~T~OV ~ND DIA~NOSTIC TEST RIT FOR
DETECTION OF ~N~I-CARDIOLIPIN
BACRGRO~ND OF T~E I~VENTIO~
There exists three types of anti-phospholipid autoantibodies.
The first anti-phospholipids were detected during the World War II mass screening for syphilis. In a number of patients with systemic lupus erythematosus ~SLE), the test ~.or syphilis yielded a false positive. ~his false positive test for syphilis eventually led to the discovery of the three types of anti-phospholipid antibodies responsible for biological false positive reactions (BFP): VDRL (Venereal Disease Research Laboratory), lupus anti coagulant, and antl-cardiolipin antibodies. Although correlation studies show that all three types of anti-phospholipid antibodies associated with similar pathologies, the. three antibodies are not identical and each is indicative of differing medical risks.
Research has been performed on all o~ the anti-phospholipids;
unfortunately the tests developed for VDRL and lupus anti-coagulant have major limitations. Therefore, clinical testing and immunological studies have focused on the development of radioimmunoassays and ELISAs for detection of the third anti-phospholipid antibody, anti-cardiolipin. The anti-cardiolipin antibody has been linked with recurrent cerebral thrombosis, rec~rrent arterial ~hrombosis, recurrent abortion, thrombocytopenia J chorea, epilepsy, and idiopathic pulmonary ' : -.. .
. ' .'. ~ . ,'-: ~ .. . ,-WO90/10227 ~ ~7 ~ ~2 -2- PCT/US90/0~028 hypertension. These medical problems have been identified in a subset of SLE patients, which have a common syndrome identified as the Anti-Cardiolipin Syndrome.
The reasons for the strong association between thrombosis and anti-cardiolipin antibodies has not been determined. Two hypotheses have been tendered: (l) a reaction between the phospholipids in endothelial cell membranes which effect the release of prostacyclin; or (2) an action of anti-cardiolipin antibodies ~aCL) against the phospholipids în the platelet membrane. Regardless of the mechanisms which link aCL and thrombosis, the relationship between high levels o~ aCL and further occurrence of thrombosis is well established.
Although the biological mechanisms which trigger aCL to react causing the clinical manifestations of aCL syndrome to appear are not fully understood, the clinical significance of monitoring aCL is substantial. High levels of aCL appear to correlate well with renewed disease activity. ACL levels should be monitored in SLE patients undergoing anti-coayulant therapy, in patients with previous thrombosis, in patients under 45 who have had myocardial infarctions, in patients with venous thrombos~s, or placental infarctions or recurrent incidence of intra-uterine death and spontaneous abortions, and in patients electing to take oral contraceptives to ; determine th~ statuC o~ their aCL levels.
~3~ ~77~2 The development of a stable, reproducible anti-cardiolipin antibody test has become an international project. In April of 1986, scientists from thirty laboratories in Britain, the U.S.A., France, Italy, New Zealand, the Netherlands, and Sweden all participated in an international study to evaluate anti-cardiolipin (aCL) tests. At least three types of (aCL) tests have been developed: a diagnostic kit based on the ELISA method (by Cheshire Diagnostics, Cheshire, UK), a solid phase radioi~munoassay method (Harris, et. al., The Lancet, 1211-1214, [Nov. 26, 1983~), and a sandwich ELISA technique (E.N. Harris, et. al., Clin. Exp. Immunol. 68, 215-225 [1987]). Anti-phospholipid syndrome can cause a patient to have a high level of IgG aCL alone, or a high level of IgM
aCL; therefore, these methods are designed to measure the concentration of both IgG and IgM anti-cardiolipins.
A variety of different techniques have been developed in the search for a stable, reproducible, speedy method of detecting IgG and IgM aCL. Although each method has shown some promise, none of the methods has ade~uately met the requirements necessary to be a suitable assay method. Examples of the c various limitations of the prior techniques follow.
Firstly, RIA techniques have been developed for anti-cardiolipin concentration measurements. RIAs provide sensitive and accurate measurements of high and medium levels of IgM and IgG concentrationsO However, RIAs are plagued with the hazards and expense associated with radioactive material.
,' ' . ' ' ' ::
.
,:
: . , ' ; . . .:
W09OtlO227 PCT/US90/01028 ~ -4-.
?.a 4~
one specific RIA develped by E.N. Harris for the detection of anticardiolipin antibodies is 400 times more sensitive than the preceding test, which was the precipitaltion method used in the Venereal Disease Reference Laboratory test. Although this RIA was more sensitive than the previous test, it unfortunately had drawbacks of its own. The run-time of this test is twenty-two hours, which makes this test impractical in clinical laboratories.
Secondly, aCL ELISAs have been developed for routine diagnostic testing in clinical laboratories. Unfortunately, ELISAs have not been able to detect low concentrations o~ IgG
or IgM anti-cardiolipin antibodies. The scientific community has attempted to standardize results to avoid the lack of sensitivity in the low levels of positive (S. Loizon, 1985 Chem. Exp. Immunol. 62, 738-745). This lack of sensitivity has lead to a host of false negative test results, which renders these tests unsuitable for diagnosis or monitoring of a subclass o~ patients.
An ELISA for aCL has been produced as a diagnostic kit by Cheshire Diagnostics Limited. A disadvantage is that this test kit has a shel~ e of only 12 weeks from the date of ~anufacture, and problems with variations in results, as evidenced by the kits Interpre~tation o~ Results section which requires a repeat of tests with results in the IgG and IgM
bordering positive range. As a consequence, to overcome the ~O90/10227 ~ 7 7 4 2 PCT/US9~/0102~
limitation of insensitivity to low levels of aCL, repeat tests must be run increasing the CGSt to the patient and increasing the work time expended by lab personnel. However, the test kit's run time of 2 l/2 hours is substantially less than most other aCL assays. Development of a stable, speedy ELISA
capable o~ accurately measuring low levels of anti-cardiolipin antibodies is essential to surmount the problems of the prior methods.
It is therefore an objective of the present invention to provide compositions, methods, and articles for the detection of aCL antibodies at low, medium, and high levels of concentration. It is the further objective of th1s invention to overcome the aforementioned length of run time, and stability and sensitivity disadvantages inherent in other methods of detection of anti-cardiolipin antibodies. It is furthermore an objective of this invention to provide a novel, highly adaptable, readily utilizable means ~or quantitative detection of anti-cardiolipins, and further to provide test kits which use such a technique for the purpose of clinical detection, or any other purpose associated with human or animal medical testing.
BRI~F 8~RY_OF ~HB I~V~TIO~
The present invention provides no~el compositions and novel ~ethods ~or performing a sandwich assay for the detection of I~M or IgG (aCL) antibody, for the purpos o~ identification, . . , . ~, :
. . .
DETECTION OF ~N~I-CARDIOLIPIN
BACRGRO~ND OF T~E I~VENTIO~
There exists three types of anti-phospholipid autoantibodies.
The first anti-phospholipids were detected during the World War II mass screening for syphilis. In a number of patients with systemic lupus erythematosus ~SLE), the test ~.or syphilis yielded a false positive. ~his false positive test for syphilis eventually led to the discovery of the three types of anti-phospholipid antibodies responsible for biological false positive reactions (BFP): VDRL (Venereal Disease Research Laboratory), lupus anti coagulant, and antl-cardiolipin antibodies. Although correlation studies show that all three types of anti-phospholipid antibodies associated with similar pathologies, the. three antibodies are not identical and each is indicative of differing medical risks.
Research has been performed on all o~ the anti-phospholipids;
unfortunately the tests developed for VDRL and lupus anti-coagulant have major limitations. Therefore, clinical testing and immunological studies have focused on the development of radioimmunoassays and ELISAs for detection of the third anti-phospholipid antibody, anti-cardiolipin. The anti-cardiolipin antibody has been linked with recurrent cerebral thrombosis, rec~rrent arterial ~hrombosis, recurrent abortion, thrombocytopenia J chorea, epilepsy, and idiopathic pulmonary ' : -.. .
. ' .'. ~ . ,'-: ~ .. . ,-WO90/10227 ~ ~7 ~ ~2 -2- PCT/US90/0~028 hypertension. These medical problems have been identified in a subset of SLE patients, which have a common syndrome identified as the Anti-Cardiolipin Syndrome.
The reasons for the strong association between thrombosis and anti-cardiolipin antibodies has not been determined. Two hypotheses have been tendered: (l) a reaction between the phospholipids in endothelial cell membranes which effect the release of prostacyclin; or (2) an action of anti-cardiolipin antibodies ~aCL) against the phospholipids în the platelet membrane. Regardless of the mechanisms which link aCL and thrombosis, the relationship between high levels o~ aCL and further occurrence of thrombosis is well established.
Although the biological mechanisms which trigger aCL to react causing the clinical manifestations of aCL syndrome to appear are not fully understood, the clinical significance of monitoring aCL is substantial. High levels of aCL appear to correlate well with renewed disease activity. ACL levels should be monitored in SLE patients undergoing anti-coayulant therapy, in patients with previous thrombosis, in patients under 45 who have had myocardial infarctions, in patients with venous thrombos~s, or placental infarctions or recurrent incidence of intra-uterine death and spontaneous abortions, and in patients electing to take oral contraceptives to ; determine th~ statuC o~ their aCL levels.
~3~ ~77~2 The development of a stable, reproducible anti-cardiolipin antibody test has become an international project. In April of 1986, scientists from thirty laboratories in Britain, the U.S.A., France, Italy, New Zealand, the Netherlands, and Sweden all participated in an international study to evaluate anti-cardiolipin (aCL) tests. At least three types of (aCL) tests have been developed: a diagnostic kit based on the ELISA method (by Cheshire Diagnostics, Cheshire, UK), a solid phase radioi~munoassay method (Harris, et. al., The Lancet, 1211-1214, [Nov. 26, 1983~), and a sandwich ELISA technique (E.N. Harris, et. al., Clin. Exp. Immunol. 68, 215-225 [1987]). Anti-phospholipid syndrome can cause a patient to have a high level of IgG aCL alone, or a high level of IgM
aCL; therefore, these methods are designed to measure the concentration of both IgG and IgM anti-cardiolipins.
A variety of different techniques have been developed in the search for a stable, reproducible, speedy method of detecting IgG and IgM aCL. Although each method has shown some promise, none of the methods has ade~uately met the requirements necessary to be a suitable assay method. Examples of the c various limitations of the prior techniques follow.
Firstly, RIA techniques have been developed for anti-cardiolipin concentration measurements. RIAs provide sensitive and accurate measurements of high and medium levels of IgM and IgG concentrationsO However, RIAs are plagued with the hazards and expense associated with radioactive material.
,' ' . ' ' ' ::
.
,:
: . , ' ; . . .:
W09OtlO227 PCT/US90/01028 ~ -4-.
?.a 4~
one specific RIA develped by E.N. Harris for the detection of anticardiolipin antibodies is 400 times more sensitive than the preceding test, which was the precipitaltion method used in the Venereal Disease Reference Laboratory test. Although this RIA was more sensitive than the previous test, it unfortunately had drawbacks of its own. The run-time of this test is twenty-two hours, which makes this test impractical in clinical laboratories.
Secondly, aCL ELISAs have been developed for routine diagnostic testing in clinical laboratories. Unfortunately, ELISAs have not been able to detect low concentrations o~ IgG
or IgM anti-cardiolipin antibodies. The scientific community has attempted to standardize results to avoid the lack of sensitivity in the low levels of positive (S. Loizon, 1985 Chem. Exp. Immunol. 62, 738-745). This lack of sensitivity has lead to a host of false negative test results, which renders these tests unsuitable for diagnosis or monitoring of a subclass o~ patients.
An ELISA for aCL has been produced as a diagnostic kit by Cheshire Diagnostics Limited. A disadvantage is that this test kit has a shel~ e of only 12 weeks from the date of ~anufacture, and problems with variations in results, as evidenced by the kits Interpre~tation o~ Results section which requires a repeat of tests with results in the IgG and IgM
bordering positive range. As a consequence, to overcome the ~O90/10227 ~ 7 7 4 2 PCT/US9~/0102~
limitation of insensitivity to low levels of aCL, repeat tests must be run increasing the CGSt to the patient and increasing the work time expended by lab personnel. However, the test kit's run time of 2 l/2 hours is substantially less than most other aCL assays. Development of a stable, speedy ELISA
capable o~ accurately measuring low levels of anti-cardiolipin antibodies is essential to surmount the problems of the prior methods.
It is therefore an objective of the present invention to provide compositions, methods, and articles for the detection of aCL antibodies at low, medium, and high levels of concentration. It is the further objective of th1s invention to overcome the aforementioned length of run time, and stability and sensitivity disadvantages inherent in other methods of detection of anti-cardiolipin antibodies. It is furthermore an objective of this invention to provide a novel, highly adaptable, readily utilizable means ~or quantitative detection of anti-cardiolipins, and further to provide test kits which use such a technique for the purpose of clinical detection, or any other purpose associated with human or animal medical testing.
BRI~F 8~RY_OF ~HB I~V~TIO~
The present invention provides no~el compositions and novel ~ethods ~or performing a sandwich assay for the detection of I~M or IgG (aCL) antibody, for the purpos o~ identification, . . , . ~, :
. . .
2`~ 2 -6-or quantitation. The present invention utilizes in its broadest sense, anti-phospholids antibodiles, which have a particular affinity for association with cardiolipin. As described herein, the anti-cardiolipin antibodies in human serum are employed to directly a~fix to the pre-coated cardiolipin, and furthermore are specifically selected to have an affinity for an enzyme conjugated goat anti-human IgM, or an enzyme conjugated goat anti-human IgG antibody, which produce, throu~h enzymatic action with the substrate, a colored by-product which is detectable and q~antitatable using standard photometric instrumentation. This color change, which is generally measured as optical density, is in direct relationship to the concentration of IgG or IgM present in the sample solution. (~he anti-human antibody can be obtained from a variety of differing animal species.) The REAADSR test kit is a sandwich ELISA that employs pre-coated suitable solid support, such as test tubes, plates or wells (hereinafter referred to as wells or microwells). The coating which is advantageously utilized to allow adherence of the cardiolipin to the side walls and to the bottom of the wells is methylated bovine serum albumin (mBSA). The mBSA
provides a positively charged surface which enhances the adherence of the cardiolipin to all surface areas of the well.
While methylated serum preparations have frequently been utilized in anti-DNA ELISA methods, it is unique and highly surprising to find that a coating of methylated bovine serum on a solid support affixes cardiolipin in an even WO90/10227 PCT/US90/010~8 ~7~ 2~ 177~2 concentration throughout thP well without the typical problem of the formation of globules of cardiolipin on the bottom of the well. In the practice of this invention protami~e sulfate as well as functionally equivalent substitutes have been found to be capable of forming a positively charged surface;
however, due to cross reactivity of some of these substrates, mBSA is the preferred coating. The utili~ation of a methylated bovine serum underlying the cardiolipin antigen coating provides for pre-treated wells which have a shelf life of six months to one year; furthermore, the wells also provide a high level of reproducibility of results.
The reproducibility of results from the present invention is associated with the mBSA and also with the next two steps of forming the pre-treated wells; the drying and the addition of a hydrolyzed casein blocker. A casein-type blocker has been used in various E~ISA techniques (Robert F. Bogt [1987] J.
Immunological Methods, lOl, 43-50) to prevent through a protein-plastic interaction non-specific binding to plastic.
It is an unaxpected realizatior1 that a microwell coated with hydrolyzed casein blocker properly dried and stored at 4 degrees C in a sealed plastic bag maintains a consistent inhibition o~ non-specific binding over an extended period of time.
Although the direct mechanisms by which the drying process and the blocker increase the stability and shelf life of the .
. .
.
WO90/10227 PCTtUS90/~1028 ~c~ -8-microwells is not fully understood, it is clear that the storage time is increased by these two processes.
A variety of differing blocking age~ts could be utilized which are functionally equivalent to or chemically related to the casein blocking agent; for example, BSA and porcine thyroglobulin, dried milk, whole goat serum, etc., however the most preferable is the hydrolyzed casein (commercially available by Sigma) due to its high level of inhibition of non-specific binding and its storage stability.
The pre-treated wells are then used to detect the presence of anti-cardiolipin antibody in the samples. The plasma or serum samples are prepared with a sample diluent and are then assayed by an immunoassay technique, the ELISA and the fluorescent immunoassay (FIA~ formats being the preferred methods, though it is possible to perform a RIA or a luminescent assay with little modification.
The assays depicted in the following examples have an approximate run time of 45 minutes. The wells when exposed to the samples are provided with approximately 15 minutes to allow the binding process to go to completion. Then the labelled goat anti-human antibodies are exposed to the wells and a similar 15 minute incubation at room temperature is provided. If the anzyme format is utilized, the substrate is added and lO minutes is allotted for the production of the color. If a fluorescent marker was used on the anti-human W090/l0227 PCT/~S90/~1028 _9_ -2~77 42 antibody then no substrate i5 needed, therefore the run time is shortened by 10 minutes reducing it to 35 minutes.
Subsequent qualitative and quantitative detec:tion of the anti-cardiolipin antibody is relatively simple if the format is either an ELISA or a FIA. Although horserad.ish peroxidase was used in the examples, numerous enzyme-conjugated antibodies and fluorescent marked antibodies specific for any o~ the immunoglobulin classes can be substituted to perform the assay. The quantitation of the anti-cardiolipin antibodies present is accomplished by the related instruments; the ELISA
technique utilizes a spectrophotometer, and the FIA technique utilizes a microfluorometer. Use of the ELISA techniques were first described by Engvall and Perlman (~1971] Immunochemistry 8, 871-874 and tl972] J. Immunology 109, 129-135), and The Enzyme Linked Immunosorbent Assay (ELISA) by Voller, A., Bidwell, D.E. and Bartlett, A., (1979) Dynatech Laboratories, Inc., Alexandria Virginia, both o~ which are, in their totality, incorporated herein by reference.
DBTAI~ED DE~CRIP~ION OF T~E INV~NTION
The following definitions are supplied for the purpose o~
clarifying the invention and are not intended to limit the scope of the invention:
Methylated _8OV ne _Serum Albumin Solution: Unless otherwise sp~cified, is intended to mean a solution with 20 micrograms '~`` "' ' ~ ' ' ':
'. ' . , :
2~Ll;~7'~ -lo-of methylated bovine serum ~lbumin (mBSA) dissolved in water at a ratio of 1 ml of distilled water to 20 micrograms of (mBSA). A substitute for mBSA is protamine sulfate or any other chemical or chemical process capable of producing a slightly positively charged coating which is evenly distributed over the surface of the microtitre well.
PBS Solution: A .01 molar solution of buffer containing 1.43 g potassium phosphate, dibasic, .25 g potas~ium phosphate, monobasic, and 8.5 g sodium chloride in one liter of water.
The pH is 7.3 +/- .1.
Cardiolipin ,(~rom beef heart~_Solution: Purified cardiolipin (Sigma) is dissolved in 100% denatured ethanol at 20 micrograms cardiolipin per ml of solution. Alternative sources of antigen includes, but are not limited to, phosphatidylserine, phos-phatidylcholine, phosphatidylethano-lamine, phosphatidylglycerol, phosphatidylinositol.
Casein ,B,loc,k,er Sol~ut,ion: 2 ml glyercol, 10 grams sucrose and 15 milligrams of hydrolyzed casein added to TEN buffer for a total volume of 100 ml. Adjust pH to 7.3 +/- .1.
TEN Bu,ffer: Is made by adding 6.1 g TRIS, .38 g EDTA, 8.8 g NaCl, 3.8 ml of concentrated HCL to 900 ml deionized water.
Adjust pH to 7.3 and add deionized water ~ufficient to give 1000 milliliter total volume.
' ' ' ~ ' ' ' . `'' . :
. . .
~,, ., ~ - :, :, ' ' , , ' : " ,: ,~
11- 2~77~2 Anti-~hos~holipid Antibody: Circulating autoantibodies directed against complex lipid antigens such as cardiolipin.
Double AntibodY Sandwich ELISA or FIA: An assay utilizing a solid support that is coated with material which detects and binds the-antibody of interest to the coated surface. To render a signal, a second conjugated antibody with an affinity for the previously bound antibody is exposed to the coated surface. The binding of the conjugated antibody to the original antibody makes the sandwich. If the sandwich assay is an ELISA then the second antibody is conjugated with an enzyme and a substrate is used to produce a color. If the assay is an FIA then the second antibody is marked with a fluorescent tag and a substrate is unnecessary.
Serum: Is intended to mean the fluidic component of any body fluid remainillg after cells and coagulable proteins such as fibrin which may be present in such body fluidic components have been removed by appropriate physical, chemical, or physicochemical means. Typically, this term refers to the residual watery fluid remaining a~ter clotting of blood and removal of the clot, but in its broad sense is intended to include the ~luidic component of cerebrospinal fluid, urine, interstitial fluid, cellular cytoplasm, and the like.
Sample Diluent- A liter solution containing 100 mls of native bovine serum, 1.42 g of potassium phosphate (dibasic~, .26 g of potassium phosphate (monobasic), 1 g of sodium azide, and - . . .
,. ' , , ' . ' :
,.
.. . . .
WO90/10227 ~ 12- PCT/US90/01028 8.6 g of sodium chloride dissolved in 900 mls of water. l ml of stock green dye is added to the solution, if a FIA format is used then the dye is unnecessary. The solution is then filtered through a .2 micron filter.
Sam~le Diluent Solution: lO microliterc of sera or plasma dissolved in 500 microliters o~ sample diluent.
Con~uaate Diluent: A phosphate bu~fer, and protein stabilizer, plus .02% thimerosal adjusted to a pH of 7.5, (commercially available from Medix) into which is added a protease inhibitor, aprotinin, (commercially available from Miles P~ntex) at .01% of the volume of the buffer.
Workin~ _Con~u~ated Antibody Solution: l volume of concentrated conjugated antibodies/3000 volume o~ conjugate diluent. The dilution is subject to change based on the concentration level o~ the conjugated antibody.
Coniuqated Antibodies: For an ELISA, antibodies were chemically conjugated with horseradish peroxidase. For a FIA, antibodies were chemically conjugated with Fluorescein Isothiocyanate.
Immunoqlobulin. Any member of the gammaglobulin fraction of serum possessing the ability to bind another agent.
:, . . : ' : ' . ~ '' ,:
': ' , ' : '~
WO90/10~27 PCTtUS90/01028 -13- 20 ~ 2 Antibod~: A class of serum proteins which specifically bind to an antigen which induced the formation of the antibody.
Antiqen: Molecules ~rom whatever source nature or man-made) which induce an immune reaction when recognized by the host's immune system.
Immunoalobulin Classes: Antibodies separated by electrophoretic mobility specifically IgG and IgM.
Substrate Solution: To quantitate the conjugated antibody, a buffered solut.ion containing (3,3',5,5') Tetramethylbenzidine/
hydrogen peroxide, (commercially available from Kirkegaard Perry) was used. The substrate solution will vary according to the enzyme used or the test format used.
Labelled Antibodies: Any antibody substance which has been covalently or otherwise combined with a molecule or ion for the purpose of selectively identifying that group of antibodies. Such adduct molecules or ions include enzymes, fluorescent substances, radionuclides, and the like.
Labelled Antiaens: Any antigen substance which has been covalently or otherwise combined with a molecule or ion for the purpose of selectively identifying that group of antigens.
Such adduct molecules or ions include enzymes, fluorescent substances, radionuclides, and the like.
''; : .. .
; , '` ~ ' ' - : ,:
; . : . .
:. . ' ~ :. ,:
. . . , ~ . :
; . :
WO90~10~27 PCTIUS90/01028 ~77 ~2 Optical Density ~OD) or Absorbance: A number which refers to the colox absor~ance of a solution. Optical density is related to the percent of light transmitted through the solution by the following formulate: OD = 2-log(percent transmittance).
The preferred embodiment of the method and apparatus for the detection of anti-cardiolipins in sera is a diagnostic test kit. The optimized kit contains:
1 vial (50 ml) Sample Diluent - green solution: contains 0.1 sodium azide.
1 vial (0.25 ml) Human Negative Control. Contains 0.1% sodium azide.
4 vials (0.25 ml) Human Positive Controls - anti-cardiolipin activity on the label. Contains 0.1% sodium azide.
(Controls included for GPL and MPL).
5 vials (0.25 ml) of Calibrator sera~ standardized against Nigel Harris' re~erence preparations.
12 pre-coated B~well Microwell Strips with frame holder.
1 vial (8 ml) Conjugated Antibody Working Solution containing horseradish p roxidAse-conjugated anti-human IgM.
- .. . .
~ :
, ., : . ~. :
.
., , .. . .
~' : ' ' :
~ 77~2 1 vial (8 ml) Conjugated Antibody Working Solution containing horseradish peroxidase-conjugated anti human IgG.
1 bottle (8 ml) TMB Substrate Solution A - containing 3,3',5,5', tetramethylbenzidine in buffer.
1 bottle (8 ml) TMB Substrate Solution B - containing hydrogen peroxide 1 bottle (12 ml) Stop Reagent: contains 2.5N H2SO4 ** 1 N
HCL may also be used as stop reagent.
1 packek - Phosphate Buffered Saline ~PBS) - reconstitutes to 2 liters of O.O1 M PBS, pH 7.4.
Plate templat~
Two sets of Calibrator sera have been included in order to generate a standard curve, one set for IgM antibodies (MPL), and one set for IgG antibodies (GPL). These have been standardized against the Reference Sera proposed by Dr. Nigel Harris. The amounts supplied and the levels of anti-cardiolipin activity in the controls and calibrators can be varied without affecting the performance of the assay.
::
.' , '' .
WO90/10227 PCT/US9~/0102X
%~77~2 This kit is designed to be used in clinical laboratories to measure l,e~,els o~ anti-cardiolipin in approximately 45 minutes. The results of the kit's measurement are adequately reproducible within and between assays. Due to the ~tability of the pre-coated wells and of the various reagents used in the assay, the shelf life of the kit is greater than six months. What follows is a description of a preferred embodiment of the pre-coated wells of the present invention, along with the preferred method for preparation of and utilization of the various elements of the kit to detect anti-cardiolipins in the sample of body fluid.
Step l: Preparatlon o~ the Pre-Coated Microtiter Wells: 20 ug/ml methylated bovine serum albumin is dissolved in water.
This solution is used to render the surface of the microtitre wells slightly positively charged. To affix m8SA to the surface of the wells, lO0 microliters of the prepared solution is placed in wells that have been rinsed with deionized water and thoroughly drained. Thus, 2 microgram~ of mBSA is placed in each individual well. Examples of microwells that have been used are Dynatech Immulon 2, Dynatech Immulon 4, or Nunc Maxisorp. The wells are incubated at room temperature for two hours, and when removed the excess solution is shaken from the plate and the wells are inverted to drain thoroughly.
Next, the ligand or antigen is diluted and coated to the receiving sur~ac of the wells. Cardiolipin is added to lO0~
denatured ethanol with the finai concentration of cardiolipin :' : . ' ~ ' - ,: .' ,. . . ~ .. . . .
.: . .. . .
' , in the resultant solution being 20 micrograms~ml weight per volume. lO0 microliters of this s~lution i5 placed in contact with each well and the solution is allowed to completely evaporate at room t~mperature. This evaporation process lasts about 18 to 24 hours.
The casein blocking step decreases th2 non-specific binding that can occur due to protein-plastic interaction~ Hydrolyzed casein can be commercially obtained from Sigma, and the blocking solution is prepared by mixing 2 ml glycerol, lO g sucrose, and 15 milligrams of hydrolyzed casein, and adding sufficient TEN buffer to make 100 ml of solution. The pH is adjusted to 7.3 +/- .1. Next, 200 ul of caseln blocking solution is dispensed into each well, and the wells are incubated at 4 degrees C overnight. Following incubation the wells are inverted, shaken to remove excess solution, and allowed to drain for 15 minutes. The wells are turned upright and allowed to dry at room temperature for at least 24 hours.
This completes the coating of the microtiter wells and each kit is then supplied with 96 coated wells. The shelf life of the pre-treated wells stored at 4 degrees C in a sealed plastic bag is up to one year.
':
vell~ Sample Diluent is supplied in the kit as 50 ~1 of a green solution. To prepare a 1000 ml solution of sample diluent lO0 milliliters o~ native bovine serum, l.42`g , .
..
WO90/10227 P~T/US90/01028 ~ 18-of Potassium Phosphate (dibasic3, .26 g of Potassium Phosphate (monobasic~, 1 gram of sodium azide, and 8 0 6 g of sodium chloride, 1 ml of stock green dye are dissolved in demineralized water -sufficient to make 1000 milliliters of solution. This solution is then filtered through a .2 micron filter and stored at 4 degrees C. Prior to contacting the body fluid with khe prepared wells, the serum is diluted by adding an aliquot of serum to the Sample Diluent in a 1:50 ratio (volume of serum:volume o~ sample diluent), although the dilution is not critical and depends upon the nature of the body fluid and the assay techniques employed.
100 microliters of the diluted sample is then placed into the appropriate wells. Adherence of the anti-cardiolipin ~rom the body fluid to the pre-coated wells is enhanced by room temperature incubation for fifteen minutes.
Following incubation to achieve antibody adherence, the excess solution is shaken from the wells removing nonbound antibodies that are present in the sample. This is done since there are many more free antibodies than there are bound to the cardiolipin on the wells and residual free antibodies would elevate background absorbance values. The wells a~e then washed four times with phosphate-buffered saline, and drained.
Step 3 Assay for Anti-Cardioli~in_Antibodies A~fixed to the Plate: Standard enzyme-linked assay techniques, previously described, are used for this assay, althouyh any suitable - . . . ....................... .
.
.
. .
WO90/10227 PCT/~S90/0~028 2~4~742 means of detection such as radioactive labeling, Eluorescence, or the like can be employed. For the examplas described hereinafter, anti-human IgG and IgM induced in goats was used to ascertain whether anti-cardiolipin IgG and IgM antibodies were present. These antisera were linked to horseradish peroxidase, an enzyme which yields a colored product whenever one of its substrates is present together with hydrogen peroxide. The substrate should be chosen to be consistent with the enzyme conjugated to the antibody. For the examples described hereinafter, the substrate was (3,3',5,5') Tetramethylbenzidine and hydrogen peroxide.
The kit contains two 8 ml vials of previously diluted conjugated antibody, one contains anti-human IgM antibody conjugated to horseradish peroxidase, and the other contains anti-human IgG similarly conju~ated. ~o prepare the conjugate diluent used to dilute the conjugated antibody a phosphate buffer with protein stabilizer and .02% thimerosal solution at pH 7.4 (commercially available from Medix) was mixed with protease inhibitor (commercially available from Miles Pentex) at a .01% ratio of inhibitor to volume of buffer. This diluent solution enhances the stability of the conjugated antibody. ~he working conjugated antibody solution is prepared at a ratio of 1:3000; one part of concentrated conjugated IgM or IgG antibodies is aliquoted into 3000 parts conjuyate diluent. This dilution ratio will vary depending on concentration ffl concentrated conjugated antibody~
2~ ~7 ~`2- -20-The enzyme conjugated goat anti-human antibody solution, prepared as described, is then added to each well in lOO
microliter increments. Binding of these antibodies to the anti-cardiolipin is permitted for at least 15 minutes at room temperature. The wells are emptied of their contents, and washed ~our time~ with PBS and allowed to drain.
The presence of a labeled antibody, as previously described, is determined by incubating the plates with a solution of (3,3',5,5') Tetramethylbenzidine and buffered hydrogen peroxide. This solution is supplied in the kit in two 8 ml vials; one contains (3,3',5,5') Tetramethylbenzidine; the other bottle contains hydrogen peroxide. The separate vials are necessary due to the interaction between the two solutions. The two solutions are mixed in a one ko one ratio just prior to use, and 100 microliters of the mixed solution is dispensed into each microwell. The reaction is permitted to continue for l0 minutes at room temperature, or until sufficient color appears to be read on the spectrophotometric device used. The reaction is subsequently stopped through the addition of 100 microliters of 2.5 normal sulfuric acid to each well and the intensity o~ color (the optical density, or OD or abscrbance) is read by a spectrophotometric device such as as a Dynatech MR600 or the like.
A~ with any enzyme linked immune assay, the resultant color of the reaction product is proportional tv the number of conjugated antibodies which have bound to the anti-:. ' . ' , . -.. . .
; . . '' ' ' ' , :' ' '' ' ' . ," ' '' .. , ~ ~.
' ' .: ' : ' ~ : :
1.
.. . . . . . . .
WO90/~0227 PCT/~S90/01028 -21- 2 ~ ~77 ~2 cardiolipin. For most cases, the number of bound conjugated antibodies is linearly related to the number of anti-cardiolipins. Hence, as the amount of conjugated antibodies ~ixed on the film increases, so does the optical density, or absorbance o~ the enzyme reaction.
, . ' ' .
?.~ 4r~
CARDIOLIPIN
EXAMPT.~ 1 In a preferred embodiment polystyrene microtiter wells were coated with a ~ilm of methylated bovine serum albumin (mBSA) by the following procedure:
1. 20 ug/ml of methylated bovine serum al~umin in powdered form (available commercially from Sigma) was dissolved in water.
2. The methylated bovine serum albumin solution was placed in the microwells in aliquots of 100 microliters per well, and incubated at room temperature for two hours.
3. After the incubation, the solution was emptied ~rom the wells and they were inverted to drain.
provides a positively charged surface which enhances the adherence of the cardiolipin to all surface areas of the well.
While methylated serum preparations have frequently been utilized in anti-DNA ELISA methods, it is unique and highly surprising to find that a coating of methylated bovine serum on a solid support affixes cardiolipin in an even WO90/10227 PCT/US90/010~8 ~7~ 2~ 177~2 concentration throughout thP well without the typical problem of the formation of globules of cardiolipin on the bottom of the well. In the practice of this invention protami~e sulfate as well as functionally equivalent substitutes have been found to be capable of forming a positively charged surface;
however, due to cross reactivity of some of these substrates, mBSA is the preferred coating. The utili~ation of a methylated bovine serum underlying the cardiolipin antigen coating provides for pre-treated wells which have a shelf life of six months to one year; furthermore, the wells also provide a high level of reproducibility of results.
The reproducibility of results from the present invention is associated with the mBSA and also with the next two steps of forming the pre-treated wells; the drying and the addition of a hydrolyzed casein blocker. A casein-type blocker has been used in various E~ISA techniques (Robert F. Bogt [1987] J.
Immunological Methods, lOl, 43-50) to prevent through a protein-plastic interaction non-specific binding to plastic.
It is an unaxpected realizatior1 that a microwell coated with hydrolyzed casein blocker properly dried and stored at 4 degrees C in a sealed plastic bag maintains a consistent inhibition o~ non-specific binding over an extended period of time.
Although the direct mechanisms by which the drying process and the blocker increase the stability and shelf life of the .
. .
.
WO90/10227 PCTtUS90/~1028 ~c~ -8-microwells is not fully understood, it is clear that the storage time is increased by these two processes.
A variety of differing blocking age~ts could be utilized which are functionally equivalent to or chemically related to the casein blocking agent; for example, BSA and porcine thyroglobulin, dried milk, whole goat serum, etc., however the most preferable is the hydrolyzed casein (commercially available by Sigma) due to its high level of inhibition of non-specific binding and its storage stability.
The pre-treated wells are then used to detect the presence of anti-cardiolipin antibody in the samples. The plasma or serum samples are prepared with a sample diluent and are then assayed by an immunoassay technique, the ELISA and the fluorescent immunoassay (FIA~ formats being the preferred methods, though it is possible to perform a RIA or a luminescent assay with little modification.
The assays depicted in the following examples have an approximate run time of 45 minutes. The wells when exposed to the samples are provided with approximately 15 minutes to allow the binding process to go to completion. Then the labelled goat anti-human antibodies are exposed to the wells and a similar 15 minute incubation at room temperature is provided. If the anzyme format is utilized, the substrate is added and lO minutes is allotted for the production of the color. If a fluorescent marker was used on the anti-human W090/l0227 PCT/~S90/~1028 _9_ -2~77 42 antibody then no substrate i5 needed, therefore the run time is shortened by 10 minutes reducing it to 35 minutes.
Subsequent qualitative and quantitative detec:tion of the anti-cardiolipin antibody is relatively simple if the format is either an ELISA or a FIA. Although horserad.ish peroxidase was used in the examples, numerous enzyme-conjugated antibodies and fluorescent marked antibodies specific for any o~ the immunoglobulin classes can be substituted to perform the assay. The quantitation of the anti-cardiolipin antibodies present is accomplished by the related instruments; the ELISA
technique utilizes a spectrophotometer, and the FIA technique utilizes a microfluorometer. Use of the ELISA techniques were first described by Engvall and Perlman (~1971] Immunochemistry 8, 871-874 and tl972] J. Immunology 109, 129-135), and The Enzyme Linked Immunosorbent Assay (ELISA) by Voller, A., Bidwell, D.E. and Bartlett, A., (1979) Dynatech Laboratories, Inc., Alexandria Virginia, both o~ which are, in their totality, incorporated herein by reference.
DBTAI~ED DE~CRIP~ION OF T~E INV~NTION
The following definitions are supplied for the purpose o~
clarifying the invention and are not intended to limit the scope of the invention:
Methylated _8OV ne _Serum Albumin Solution: Unless otherwise sp~cified, is intended to mean a solution with 20 micrograms '~`` "' ' ~ ' ' ':
'. ' . , :
2~Ll;~7'~ -lo-of methylated bovine serum ~lbumin (mBSA) dissolved in water at a ratio of 1 ml of distilled water to 20 micrograms of (mBSA). A substitute for mBSA is protamine sulfate or any other chemical or chemical process capable of producing a slightly positively charged coating which is evenly distributed over the surface of the microtitre well.
PBS Solution: A .01 molar solution of buffer containing 1.43 g potassium phosphate, dibasic, .25 g potas~ium phosphate, monobasic, and 8.5 g sodium chloride in one liter of water.
The pH is 7.3 +/- .1.
Cardiolipin ,(~rom beef heart~_Solution: Purified cardiolipin (Sigma) is dissolved in 100% denatured ethanol at 20 micrograms cardiolipin per ml of solution. Alternative sources of antigen includes, but are not limited to, phosphatidylserine, phos-phatidylcholine, phosphatidylethano-lamine, phosphatidylglycerol, phosphatidylinositol.
Casein ,B,loc,k,er Sol~ut,ion: 2 ml glyercol, 10 grams sucrose and 15 milligrams of hydrolyzed casein added to TEN buffer for a total volume of 100 ml. Adjust pH to 7.3 +/- .1.
TEN Bu,ffer: Is made by adding 6.1 g TRIS, .38 g EDTA, 8.8 g NaCl, 3.8 ml of concentrated HCL to 900 ml deionized water.
Adjust pH to 7.3 and add deionized water ~ufficient to give 1000 milliliter total volume.
' ' ' ~ ' ' ' . `'' . :
. . .
~,, ., ~ - :, :, ' ' , , ' : " ,: ,~
11- 2~77~2 Anti-~hos~holipid Antibody: Circulating autoantibodies directed against complex lipid antigens such as cardiolipin.
Double AntibodY Sandwich ELISA or FIA: An assay utilizing a solid support that is coated with material which detects and binds the-antibody of interest to the coated surface. To render a signal, a second conjugated antibody with an affinity for the previously bound antibody is exposed to the coated surface. The binding of the conjugated antibody to the original antibody makes the sandwich. If the sandwich assay is an ELISA then the second antibody is conjugated with an enzyme and a substrate is used to produce a color. If the assay is an FIA then the second antibody is marked with a fluorescent tag and a substrate is unnecessary.
Serum: Is intended to mean the fluidic component of any body fluid remainillg after cells and coagulable proteins such as fibrin which may be present in such body fluidic components have been removed by appropriate physical, chemical, or physicochemical means. Typically, this term refers to the residual watery fluid remaining a~ter clotting of blood and removal of the clot, but in its broad sense is intended to include the ~luidic component of cerebrospinal fluid, urine, interstitial fluid, cellular cytoplasm, and the like.
Sample Diluent- A liter solution containing 100 mls of native bovine serum, 1.42 g of potassium phosphate (dibasic~, .26 g of potassium phosphate (monobasic), 1 g of sodium azide, and - . . .
,. ' , , ' . ' :
,.
.. . . .
WO90/10227 ~ 12- PCT/US90/01028 8.6 g of sodium chloride dissolved in 900 mls of water. l ml of stock green dye is added to the solution, if a FIA format is used then the dye is unnecessary. The solution is then filtered through a .2 micron filter.
Sam~le Diluent Solution: lO microliterc of sera or plasma dissolved in 500 microliters o~ sample diluent.
Con~uaate Diluent: A phosphate bu~fer, and protein stabilizer, plus .02% thimerosal adjusted to a pH of 7.5, (commercially available from Medix) into which is added a protease inhibitor, aprotinin, (commercially available from Miles P~ntex) at .01% of the volume of the buffer.
Workin~ _Con~u~ated Antibody Solution: l volume of concentrated conjugated antibodies/3000 volume o~ conjugate diluent. The dilution is subject to change based on the concentration level o~ the conjugated antibody.
Coniuqated Antibodies: For an ELISA, antibodies were chemically conjugated with horseradish peroxidase. For a FIA, antibodies were chemically conjugated with Fluorescein Isothiocyanate.
Immunoqlobulin. Any member of the gammaglobulin fraction of serum possessing the ability to bind another agent.
:, . . : ' : ' . ~ '' ,:
': ' , ' : '~
WO90/10~27 PCTtUS90/01028 -13- 20 ~ 2 Antibod~: A class of serum proteins which specifically bind to an antigen which induced the formation of the antibody.
Antiqen: Molecules ~rom whatever source nature or man-made) which induce an immune reaction when recognized by the host's immune system.
Immunoalobulin Classes: Antibodies separated by electrophoretic mobility specifically IgG and IgM.
Substrate Solution: To quantitate the conjugated antibody, a buffered solut.ion containing (3,3',5,5') Tetramethylbenzidine/
hydrogen peroxide, (commercially available from Kirkegaard Perry) was used. The substrate solution will vary according to the enzyme used or the test format used.
Labelled Antibodies: Any antibody substance which has been covalently or otherwise combined with a molecule or ion for the purpose of selectively identifying that group of antibodies. Such adduct molecules or ions include enzymes, fluorescent substances, radionuclides, and the like.
Labelled Antiaens: Any antigen substance which has been covalently or otherwise combined with a molecule or ion for the purpose of selectively identifying that group of antigens.
Such adduct molecules or ions include enzymes, fluorescent substances, radionuclides, and the like.
''; : .. .
; , '` ~ ' ' - : ,:
; . : . .
:. . ' ~ :. ,:
. . . , ~ . :
; . :
WO90~10~27 PCTIUS90/01028 ~77 ~2 Optical Density ~OD) or Absorbance: A number which refers to the colox absor~ance of a solution. Optical density is related to the percent of light transmitted through the solution by the following formulate: OD = 2-log(percent transmittance).
The preferred embodiment of the method and apparatus for the detection of anti-cardiolipins in sera is a diagnostic test kit. The optimized kit contains:
1 vial (50 ml) Sample Diluent - green solution: contains 0.1 sodium azide.
1 vial (0.25 ml) Human Negative Control. Contains 0.1% sodium azide.
4 vials (0.25 ml) Human Positive Controls - anti-cardiolipin activity on the label. Contains 0.1% sodium azide.
(Controls included for GPL and MPL).
5 vials (0.25 ml) of Calibrator sera~ standardized against Nigel Harris' re~erence preparations.
12 pre-coated B~well Microwell Strips with frame holder.
1 vial (8 ml) Conjugated Antibody Working Solution containing horseradish p roxidAse-conjugated anti-human IgM.
- .. . .
~ :
, ., : . ~. :
.
., , .. . .
~' : ' ' :
~ 77~2 1 vial (8 ml) Conjugated Antibody Working Solution containing horseradish peroxidase-conjugated anti human IgG.
1 bottle (8 ml) TMB Substrate Solution A - containing 3,3',5,5', tetramethylbenzidine in buffer.
1 bottle (8 ml) TMB Substrate Solution B - containing hydrogen peroxide 1 bottle (12 ml) Stop Reagent: contains 2.5N H2SO4 ** 1 N
HCL may also be used as stop reagent.
1 packek - Phosphate Buffered Saline ~PBS) - reconstitutes to 2 liters of O.O1 M PBS, pH 7.4.
Plate templat~
Two sets of Calibrator sera have been included in order to generate a standard curve, one set for IgM antibodies (MPL), and one set for IgG antibodies (GPL). These have been standardized against the Reference Sera proposed by Dr. Nigel Harris. The amounts supplied and the levels of anti-cardiolipin activity in the controls and calibrators can be varied without affecting the performance of the assay.
::
.' , '' .
WO90/10227 PCT/US9~/0102X
%~77~2 This kit is designed to be used in clinical laboratories to measure l,e~,els o~ anti-cardiolipin in approximately 45 minutes. The results of the kit's measurement are adequately reproducible within and between assays. Due to the ~tability of the pre-coated wells and of the various reagents used in the assay, the shelf life of the kit is greater than six months. What follows is a description of a preferred embodiment of the pre-coated wells of the present invention, along with the preferred method for preparation of and utilization of the various elements of the kit to detect anti-cardiolipins in the sample of body fluid.
Step l: Preparatlon o~ the Pre-Coated Microtiter Wells: 20 ug/ml methylated bovine serum albumin is dissolved in water.
This solution is used to render the surface of the microtitre wells slightly positively charged. To affix m8SA to the surface of the wells, lO0 microliters of the prepared solution is placed in wells that have been rinsed with deionized water and thoroughly drained. Thus, 2 microgram~ of mBSA is placed in each individual well. Examples of microwells that have been used are Dynatech Immulon 2, Dynatech Immulon 4, or Nunc Maxisorp. The wells are incubated at room temperature for two hours, and when removed the excess solution is shaken from the plate and the wells are inverted to drain thoroughly.
Next, the ligand or antigen is diluted and coated to the receiving sur~ac of the wells. Cardiolipin is added to lO0~
denatured ethanol with the finai concentration of cardiolipin :' : . ' ~ ' - ,: .' ,. . . ~ .. . . .
.: . .. . .
' , in the resultant solution being 20 micrograms~ml weight per volume. lO0 microliters of this s~lution i5 placed in contact with each well and the solution is allowed to completely evaporate at room t~mperature. This evaporation process lasts about 18 to 24 hours.
The casein blocking step decreases th2 non-specific binding that can occur due to protein-plastic interaction~ Hydrolyzed casein can be commercially obtained from Sigma, and the blocking solution is prepared by mixing 2 ml glycerol, lO g sucrose, and 15 milligrams of hydrolyzed casein, and adding sufficient TEN buffer to make 100 ml of solution. The pH is adjusted to 7.3 +/- .1. Next, 200 ul of caseln blocking solution is dispensed into each well, and the wells are incubated at 4 degrees C overnight. Following incubation the wells are inverted, shaken to remove excess solution, and allowed to drain for 15 minutes. The wells are turned upright and allowed to dry at room temperature for at least 24 hours.
This completes the coating of the microtiter wells and each kit is then supplied with 96 coated wells. The shelf life of the pre-treated wells stored at 4 degrees C in a sealed plastic bag is up to one year.
':
vell~ Sample Diluent is supplied in the kit as 50 ~1 of a green solution. To prepare a 1000 ml solution of sample diluent lO0 milliliters o~ native bovine serum, l.42`g , .
..
WO90/10227 P~T/US90/01028 ~ 18-of Potassium Phosphate (dibasic3, .26 g of Potassium Phosphate (monobasic~, 1 gram of sodium azide, and 8 0 6 g of sodium chloride, 1 ml of stock green dye are dissolved in demineralized water -sufficient to make 1000 milliliters of solution. This solution is then filtered through a .2 micron filter and stored at 4 degrees C. Prior to contacting the body fluid with khe prepared wells, the serum is diluted by adding an aliquot of serum to the Sample Diluent in a 1:50 ratio (volume of serum:volume o~ sample diluent), although the dilution is not critical and depends upon the nature of the body fluid and the assay techniques employed.
100 microliters of the diluted sample is then placed into the appropriate wells. Adherence of the anti-cardiolipin ~rom the body fluid to the pre-coated wells is enhanced by room temperature incubation for fifteen minutes.
Following incubation to achieve antibody adherence, the excess solution is shaken from the wells removing nonbound antibodies that are present in the sample. This is done since there are many more free antibodies than there are bound to the cardiolipin on the wells and residual free antibodies would elevate background absorbance values. The wells a~e then washed four times with phosphate-buffered saline, and drained.
Step 3 Assay for Anti-Cardioli~in_Antibodies A~fixed to the Plate: Standard enzyme-linked assay techniques, previously described, are used for this assay, althouyh any suitable - . . . ....................... .
.
.
. .
WO90/10227 PCT/~S90/0~028 2~4~742 means of detection such as radioactive labeling, Eluorescence, or the like can be employed. For the examplas described hereinafter, anti-human IgG and IgM induced in goats was used to ascertain whether anti-cardiolipin IgG and IgM antibodies were present. These antisera were linked to horseradish peroxidase, an enzyme which yields a colored product whenever one of its substrates is present together with hydrogen peroxide. The substrate should be chosen to be consistent with the enzyme conjugated to the antibody. For the examples described hereinafter, the substrate was (3,3',5,5') Tetramethylbenzidine and hydrogen peroxide.
The kit contains two 8 ml vials of previously diluted conjugated antibody, one contains anti-human IgM antibody conjugated to horseradish peroxidase, and the other contains anti-human IgG similarly conju~ated. ~o prepare the conjugate diluent used to dilute the conjugated antibody a phosphate buffer with protein stabilizer and .02% thimerosal solution at pH 7.4 (commercially available from Medix) was mixed with protease inhibitor (commercially available from Miles Pentex) at a .01% ratio of inhibitor to volume of buffer. This diluent solution enhances the stability of the conjugated antibody. ~he working conjugated antibody solution is prepared at a ratio of 1:3000; one part of concentrated conjugated IgM or IgG antibodies is aliquoted into 3000 parts conjuyate diluent. This dilution ratio will vary depending on concentration ffl concentrated conjugated antibody~
2~ ~7 ~`2- -20-The enzyme conjugated goat anti-human antibody solution, prepared as described, is then added to each well in lOO
microliter increments. Binding of these antibodies to the anti-cardiolipin is permitted for at least 15 minutes at room temperature. The wells are emptied of their contents, and washed ~our time~ with PBS and allowed to drain.
The presence of a labeled antibody, as previously described, is determined by incubating the plates with a solution of (3,3',5,5') Tetramethylbenzidine and buffered hydrogen peroxide. This solution is supplied in the kit in two 8 ml vials; one contains (3,3',5,5') Tetramethylbenzidine; the other bottle contains hydrogen peroxide. The separate vials are necessary due to the interaction between the two solutions. The two solutions are mixed in a one ko one ratio just prior to use, and 100 microliters of the mixed solution is dispensed into each microwell. The reaction is permitted to continue for l0 minutes at room temperature, or until sufficient color appears to be read on the spectrophotometric device used. The reaction is subsequently stopped through the addition of 100 microliters of 2.5 normal sulfuric acid to each well and the intensity o~ color (the optical density, or OD or abscrbance) is read by a spectrophotometric device such as as a Dynatech MR600 or the like.
A~ with any enzyme linked immune assay, the resultant color of the reaction product is proportional tv the number of conjugated antibodies which have bound to the anti-:. ' . ' , . -.. . .
; . . '' ' ' ' , :' ' '' ' ' . ," ' '' .. , ~ ~.
' ' .: ' : ' ~ : :
1.
.. . . . . . . .
WO90/~0227 PCT/~S90/01028 -21- 2 ~ ~77 ~2 cardiolipin. For most cases, the number of bound conjugated antibodies is linearly related to the number of anti-cardiolipins. Hence, as the amount of conjugated antibodies ~ixed on the film increases, so does the optical density, or absorbance o~ the enzyme reaction.
, . ' ' .
?.~ 4r~
CARDIOLIPIN
EXAMPT.~ 1 In a preferred embodiment polystyrene microtiter wells were coated with a ~ilm of methylated bovine serum albumin (mBSA) by the following procedure:
1. 20 ug/ml of methylated bovine serum al~umin in powdered form (available commercially from Sigma) was dissolved in water.
2. The methylated bovine serum albumin solution was placed in the microwells in aliquots of 100 microliters per well, and incubated at room temperature for two hours.
3. After the incubation, the solution was emptied ~rom the wells and they were inverted to drain.
4. 20 microgram/ml of cardiolipin from beef heart (commercially available from Sig~a) was dissolved in 100 denatured ethanol.
5. 100 microliter of the cardiolipin solution was placed in each microwell, and incubated at room temperature ~or 18-;24 hours until the ethanol was complet~ly evaporated.
:
'- . , : '', . ~.
-WO90/~0227 PC~/US90/01028 2~77~2 . 100 ml of casein blocker solution is comprised of 2 ml glycerol, 10 g of sucrose and 15 millic~rams of hydrolyæed casein diluted to 100 ml by the addition of TEN (Tris, EDTA, NaCL) buffer. The casein blocker solution was buffered to a pH of 7.3 +~- .1. 200 microliters of blocker solution was dispensed into each microwell.
7. The wells containing casein blocker solution were incubated overnight at 4 degrees C, then the blocker solution was shaken from the wells and they were inverted and allowed to drain for 15 minutes.
8. The microwells were then uprighted and allowed to dry at room temperature for at least 24 hours.
9. The microwell plates were stored at 4 degrees C in sealed plastic bags, or used in the next step.
The cardiolipin coated wells were then used to determine the presence of anti-phospholipid antibody in serum or plasma samples drawn from individuals with:
1. no apparent pathology; (normal) 2. anti~Cardiolipin positive plasma;
3. positive RPR (rapid plasma xeagin) syphilis plasma.
WO90/10227 ~ PCT/VS90/01028 The sera and plasma had been drawn from patients known to have systemic lupus erythematosus. An anti-~cardiolipin assay, using the cardiolipin roated wells, as previously described, with a sample from one o~ the three sample groups, was performed by the procedure summariæed below:
l. A lO00 ml s~lution of Sample Diluent was comprised of lO0 mls of native bovine sexum; l.42 g of potassium phosphate dibasic, .26 g of potassium phosphate monobasic, l gram of sodium azide, and 8.5 g of sodium chloride, 1 ml of stock green dye, and 900 mls of distilled water. The diluent solution is then filtered through a .2 micro Nalzene filter and stored at 4 degrees C.
2. Sera were prepared at a l to 50 ratio of sample to Sample Diluent.
3. lO0 ul of the diluted samp}e or calibrator was transferred to the microwells in duplicate.
4. The wells were incubated at room temperature for 15 minutes. Following incubation the wells were washed four times with PBS and inverted to drain.
5. One set of duplicate microwells were exposed to a mixture containing horseradish peroxidase (HRP~ conjugated goat anti-hu~an IgM antibodies ~hereinafter referred to as M
conjugated~ and conjugate diluent; the r~maining wells , . ~ , . . .
. . .
' . . . :.
WO90/10227 PCl`/US9OtO1028 -25- 2~77~
were exposed to a mixture of HRP conjugated goat anti-human IgG antibodies (hereinafter referred to as G
conjugate) and conjugate diluent. lOO ul of either conjugate solution was dispensed to eac:h microwell.
:
'- . , : '', . ~.
-WO90/~0227 PC~/US90/01028 2~77~2 . 100 ml of casein blocker solution is comprised of 2 ml glycerol, 10 g of sucrose and 15 millic~rams of hydrolyæed casein diluted to 100 ml by the addition of TEN (Tris, EDTA, NaCL) buffer. The casein blocker solution was buffered to a pH of 7.3 +~- .1. 200 microliters of blocker solution was dispensed into each microwell.
7. The wells containing casein blocker solution were incubated overnight at 4 degrees C, then the blocker solution was shaken from the wells and they were inverted and allowed to drain for 15 minutes.
8. The microwells were then uprighted and allowed to dry at room temperature for at least 24 hours.
9. The microwell plates were stored at 4 degrees C in sealed plastic bags, or used in the next step.
The cardiolipin coated wells were then used to determine the presence of anti-phospholipid antibody in serum or plasma samples drawn from individuals with:
1. no apparent pathology; (normal) 2. anti~Cardiolipin positive plasma;
3. positive RPR (rapid plasma xeagin) syphilis plasma.
WO90/10227 ~ PCT/VS90/01028 The sera and plasma had been drawn from patients known to have systemic lupus erythematosus. An anti-~cardiolipin assay, using the cardiolipin roated wells, as previously described, with a sample from one o~ the three sample groups, was performed by the procedure summariæed below:
l. A lO00 ml s~lution of Sample Diluent was comprised of lO0 mls of native bovine sexum; l.42 g of potassium phosphate dibasic, .26 g of potassium phosphate monobasic, l gram of sodium azide, and 8.5 g of sodium chloride, 1 ml of stock green dye, and 900 mls of distilled water. The diluent solution is then filtered through a .2 micro Nalzene filter and stored at 4 degrees C.
2. Sera were prepared at a l to 50 ratio of sample to Sample Diluent.
3. lO0 ul of the diluted samp}e or calibrator was transferred to the microwells in duplicate.
4. The wells were incubated at room temperature for 15 minutes. Following incubation the wells were washed four times with PBS and inverted to drain.
5. One set of duplicate microwells were exposed to a mixture containing horseradish peroxidase (HRP~ conjugated goat anti-hu~an IgM antibodies ~hereinafter referred to as M
conjugated~ and conjugate diluent; the r~maining wells , . ~ , . . .
. . .
' . . . :.
WO90/10227 PCl`/US9OtO1028 -25- 2~77~
were exposed to a mixture of HRP conjugated goat anti-human IgG antibodies (hereinafter referred to as G
conjugate) and conjugate diluent. lOO ul of either conjugate solution was dispensed to eac:h microwell.
6. The wells were then in~ubated at room temperature for 15 minutes, to allow attachment of the conjugate. After incubation, the wells were washed four times with PBS to remove the unbound enzyme conjugated antibodies. The wells were inverted between each wash to empty the xcess fluid. After the final wash the wells were inverted to drain excess fluid.
7. Each well was assayed for horseradish peroxidase activity by adding lOO microliters of (3,3/~5,5~) Tetramethylbenzidine/ buf~ered hydrogen peroxide solution to each microwell. The wells were allowed to incubate at room temperature for lO minutes, after which lOO ul of 2.5 N H2So~ (l.O N HCL can be substituted) was added to terminate the color reaction. The presence of anti-cardiolipin was detected by the presence of color. The color was quantitated at 450 nm using a Dynatech MR600 plate reading spectophotometer which was calibrated against a water blank. Reagent controls were wells which were not contacted with sample.
D~T~C~IO~ 0~ C~RDIO~IPI~ IgG
SOUEC~ GPL OD
Cali~rator l 6 .08 Calibrator 2 l8 .17 ~ 26-Calibrator 3 35 .29 Calibrator 4 70 .52 Calibrator 5 105 .68 Refer to Figure 1 Source Mean Value GPL OD
Normal Serum < 2 .05 (positive) anti CL 46 moderate positive plasma .36 antibody plasma RPR positive plasma 45 .42 DETECTION OF CARDIOLIPIN IgM
Source MPL OD
Calibrator l 5 .08 Calibrator 2 l0 .ll Calibrator 3 20 .2 Calibrator 4 50 .45 Calibrator 5 l00 .73 Refer to Figure 2 Source Mean Value MPL OD
Normal Serum < 3 .03 (positive) anti CL 80 high positive plasma .85 antibody plasma RPR positive patient 59 .55 In each test sample, IgG and IgM aCL levels are reported in GPL and MPL units respectively. One GPL unit is defined as the cardiolipin binding activity of l ug/ml of an affinity purified Ig& aCL preparations from a standard serum. one MPL
unit is defined as the cardiolipin binding activity of 1 ug/ml of an affinity purified IgM aCL preparation from a standard serum. The unit~ have been established by Dr. Nigel Harris.
SUBS~Tl~ 1E $HEET
.
~ : : . . .
2~47742 ~XAMPLE 1'~0 To demonstrate the importance of the cardiolipin coating, a polystyrene well was uncoated and the test was run under the procedure described in Example 1. After the wells were assayed with horseradish peroxidase conjugated antibodies, there was only a slight selectivity observed, and a very high background was observed, in contrast to the background and selectivity of the coated wells.
Uncoated Calibrator~MPL Coated Well~ O.D. Wells O D.
lO0 MPL .85 .72 50 MPL .50 ~4 20 MPL .20 .19 10 MPL .12 .13 5 MPL .07 .lO
Uncoated Calibrator~GPL Co~ted ~ells O.D. Well~ O.D.
105 GPL .93 .85 70 GPL .76 .76 18 GPL .28 .36 6 GPL .13 .29 Uncoated ~ourGe~PL Co~tea Well~ O.D. Wells O.D.
~ 7 Normal Serum.04 ,09 Positive #1 .65 .50 Positiva #21.1} .~
WO90/~0227 PCT/US90/01028 t~ 4~
Vncoated 8Ource GPL ~oated_Well~ O.D. Wells O.~.
Normal Serum .0~ .25 Positive #1 .63 .39 Positive #2 .53 .44 EXANPLE THREE
Test Performed with the Diagnostic Test Kit The kit contained 96 pre-coated microwells with affinity for anti-cardiolipin and:
:.
1 vial of (30ml) Sample Diluent (green solution) - containing 0.1~ sodium azide, to be used for diluting sera samples, calibrators and controls.
1 vial of (0.25 ml) Human Negative Control.
2 vials of (0.25 ml) Human GPL Positive Control (two moderate positive controls.
2 vials of (Q.25) ml Human MPL Positive Control (moderate positive control and high positive control).
5 vials of (0.25 ml) calibrators for GPL.
5 vials of (0.25 ml) calibrators ~or MPL.
- , , . :
': ' ' . : ' , -29- 20~77~2 l vial of (8 ml) Conjugated Antibody Working Soluti4n containing horseradish peroxidase con-jugated anti-human IgM; and a second similar vial of (8 ml) Conjugated Antibody Working solution containing horseradish peroxidase conjugated anti-human IgG.
One bottle of (8 ml) of TMB Substrate solution A containing 3,3',5,5', temtramethylbenzidine, and one (8 ml) bottle of Peroxidase Substrate Solution B containing hydrogen peroxide. Solution A and B are combined to form a substrate capable of generating a colored product.
l bottle of (12 ml) Stop Reagent containing 2.5N H2SO4; ~lN
HCl may also be substituted);
A packet of Phosphate Buffered Saline ~PBS). This reconstitutes to 2 liters of 0.0l M PBS, pH 7.4.
l packet of Phosphate Buffered Saline (PBS) which reconstitutes to 2 lit~rs of 0.0l M PBS, pH 7.3, which is utilized as a wash.
l Plate template.
The plate template was labelled for sample placement in the microwells. A 1:50 dilution of the controls, calibrators and patient samples were prepared in sample diluent (green .. , . . .. - , , WO90/10227 PCT/U~9~/01028 2~7~ ~
solution). 10 ul of sample was added to 500 ul sample diluent in a one volume to 50 volume sample dilution.
100 ul of each diluted sample, control or calibrator was added to appropriate microwells. The plate was allowed to incubate for 15 minutes at room temperature. To perform the rinse step the contents of the PBS packet was added to 2 liters of reagent grade water, and the solution was mixed well, until all the crystals were dissolved. Then the buffer was used to wash the wells four times. The microwells were inverted between each wash to empty the fluid, and the wells were blotted on absorbent paper to remove residual wash fluid. Per the klt instructions, the wells were not allowed to dry-out between washes.
100 ul of conjugated antibody (red solution) was added to each well, incubated 15 minutes at room temperature, and then the wells were again washed four times with PBS solution. Next, the wells were blotted on absorbent paper to remove residual wash fluid.
The working substrate was prepared ~ust before using according to the kit instruction. Equal volumes of TMB Su~strate solution A and TMB Substrate Solution B were combined to form the color generating substrate. The kit instructed that if properly combined this substrate solution would be colorless and it was colorless. 100 ul of working substrate solution , .
WO90/1~227 PCT/US90/01028 2~77~2 was added to each well and the wells were incubated for ten minutes at room temperature.
Next 100 ul stop reagent was added to each well to end the enzyme reaction and the O.D. of aach well was read at ~50 nm against a water blank. The results were then calculated by plotting GPL or MPL calibrator values against O.D.s on linear graph paper. Sample results are read from the resulting "standard curve".
Normal Ranqes and Deqree of Positivity:
The following estimates have been established by Dr. Nigel Harris:
Normal = < 5 GPL and ~ 3 MPL
Low Positive = ~ 15 GPL and < 6 MPL
Mod Positive = 15-100 GPL and 6-60 MPL
High Positive = > 100 GPL and > 60 MPL
DETECTION OF CARDIOIIPIN IgG and IgM
Refer to Figures 3 and 4 Control results fell within predetermined ranges.
Mean Mean Controls Value ~PL O~D. ValuQ MPL OoD~
Normal 2 .7 2 .02 ~oderate positive ~6 .76 16 .32 Moderate positive 78 .99 81 .~6 High positive 78 .99 81 o96 SlJBS~lT~T~ SHE~
WO 90/10227 PCr/US90/01028 ~ean ~ean ~;our~e Value GPL O . D, alus MPL O . D.
Normal human serum 3 . 08 2 . 02 aCL ~high positive) 92 1.15 70 . 87 aCL (moderate positive) 44 . 73 17 . 34 :
, ~
.
W09OtlO227 PCT/U~90/01028 ~33~ 2 0~77 ~2 EXAMP~B 4 Samples wexe drawn from 52 patients that tested VDRL positive.
The test was run in accordance with Example 3. Approximately 17% of the samples showed positive for anti-Cardiolipin antbodies. The low positive IgG was determined to be 23 GPL, and the low positive IgM was determined to be 11 MPL. After converting the O.D. data, the following values were obtained:
Patient GPL MPL
1 5.5 4.7 2 7.~ 1.3 3 23.1 6.7 4 2.9 6.7 16.0 8.0 6 9.3 3.3 7 65.2 .6.0 8 6.5 3.3 9 39.9 12.7 9.3 7.3 11 7.8 10.7 12 4.6 4.7 13 18.3 12.0 14 12.9 2.0 28.5 6.0 16 13.2 16.0 17 14.8 4.0 18 12.6 6.7 19 9.5 4.0 6.8 7.3 21 10.3 2.7 22 3.3 2.7 23 4.1 4.0 24 7.7 6.0 5.5 5.3 26 19.9 8.0 27 7.1 1.7 28 8.7 5.8 29 7.7 5.0 4.2 2.9 31 15.5 10.8 32 ~.1 6.7 33 13.4 9.6 34 7.4 4.2 3.7 ~.3 36 31.6 6.7 ... , ~ .
.
, . ; . : .
: ,. ;,:
W~ 90/10227, P~/US90/~102 --3~
37 13.0 1.7 38 9.2 4.6 39 5.7 2.5 4.8 2.1 41 7.1 5.0 42 2.5 2.1 43 18.7 7.9 44 48 . 2 30 . O
8.~ 1.7 46 ~7.5 ~;.7 47 15.3 3.3 48 5.2 1.7 49 6.4 1.7 11.8 6.7 51 2.7 8.3 52 8.5 1.3 .
''~' , ' ' ' ~:
, ~.
.
WO90/10~27 PCT/~S90/01028 -~5-2~7~2 The following test was run according to the protocol outlined in Example 3. The samples were taken ~rom patients known to have rheumatoid arthritis, thus some anti-cardiolipin antibodies are expected to be present. A low positive was determined to be 23 GPL and 11 MPL base~ on the calibrators used. There were approximately 42% positive for IgG anti-cardiolipin antibodies and 6% positive for IgM anti-cardiolipin antibodies. The following data was generated using the present invention.
Patient Iq~ O.D. GPL IaM O.D. MPL
1 .10 6.6 .0~ 3.1 2 .28 18.3 .12 4.7 3 .44 ~28.~ .16 6.2 4 .46 *30.1 .11 4.3 .52 *34.1 .18 7.0 6 .46 *~0.1 .19 7.4 7 .51 *33.4 .16 6.2 8 .12 7.9 .10 3.9 9 .12 7.9 .08 3.1 .68 *44.5 .18 7.0 11 .20 13.1 .09 3.5 12 .13 8.5 .10 3.9 13 .20 13.1 .013 S.1 14 .31 20.3 .48 18.7 .12 7.9 .16 ~.2 16 .15 ~.~ .11 4.3 .
: ' . . , . ' ~ : ' - ~ . , . "
'': ' ' .': : . ' : ' - '' ' ~ , .: ~ : : : . ::
WO90/10227 ~ 36- PCT/US90/010~8 17 .15 9.8 .04 1.6 18 .18 11.8 .20 7.8 19 .60 *39.3 1.21 *47.2 .36 *23.6 .17 6.6 21 .22 14.4 .11 4.3 22 .38 *24.9 .12 4.7 23 .4~ *32.1 .1~ 6.2 24 .21 13.8 .07 2.7 .30 19.7 .06 2.3 26 .023 15.1 .1~ 6.2 27 .21 13.8 .21 8.2 28 .19 12.4 .10 3.9 29 .15 9.8 .16 6.2 .31 20.3 .86 33.5 31 .20 13.1 .08 3.1 32 .15 9.8 .07 2.7 33 .30 19.7 .09 3.5 34 .56 *36.7 .12 4.7 .20 14.4 .12 4.7 36 .2~3 18.3 .11 4~3 37 .32 20.1 .14 5.5 38 .56 *36.7 .07 2.7 39 .28 18.3 .11 4.3 .27 17.7 .11 4.3 41 ~41 *30~0 ol2 5~1 4~ .34 *24.9 .5 ~21.1 43 .30 21.9 .~2 5.1 44 .41 *30.0 .12 5.1 . ` ' ' , ' '' ' ' ~- ~ .. ' , - . ~ .':
. ; . .
WO90/10~27 P~TIU~90101028 _37_ 2~77~2 .32 *23.4 .09 3.8 46 .32 *23.4 .10 4.2 47 .33 *24.1 .20 8.4 48 .54 *39.5 .14 5.9 49 .21 15.4 .12 5.1 .32 *23.4 .17 7.2 51 .46 *33.6 .08 3.4 52 .23 16.8 .07 2.9 53 .05 3.7 .02 .8 54 .64 *46.8 .20 8.4 .44 *32.2 .07 2.g 56 .23 16.8 .11 4.6 57 .14 10.2 .12 5.1 58 .22 16.1 .09 3.8 59 .34 *24.9 .07 2.9 .61 *44.6 .12 5.1 61 .32 *23.4 .12 ~1 62 .51 *37.3 .09 3.8 63 .12 8.8 .10 4.2 64 .30 2~.9 .10 4.2 .34 *24.g .18 7.6 66 .37 *27.0 .10 4.2 67 .42 *30.7 .12 5.1 ~8 .~5 *40.2 .19 8.0 69 .15 11.0 .10 4.2 .36 *26.3 .39 1~.4 71 .~8 13.2 .16 6.7 72 .20 14.6 .16 6.7 ' ~ ' ' ' ''' . .:
WO90/tO227 PCT/US90/01028 ~ -38-73 ` .06 4.4 .17 7.2 74 .30 21.9 .13 5.5 .48 *35.1 .10 4.2 76 .35 *25.6 .08 3.4 77 .22 16,1 .07 2.9 78 .15 11.0 .14 5.9 79 .21 15.4 .13 5.5 .16 11.7 .18 7.6 *Positive Results.
The following test was run according to the pro~ocol outlined in Example 3. The samples were suspected of hav:ing anti-cardiolipin antibodies as the patients were all SLE patients.
The low positive was determined to be 23 GPL and 11 MPL. Seven patients were GPL positive and seven were MPL positive. The followin~ data was gathered by the test kit procedure:
PATIENT IqG O D. GPL IaM O.D. MPL
1 O43 *26.4 .20 10.2 2 .11 7.9 .14 *12.4 3 .25 17.9 .04 3.6 4 .10 7.2 .0~ 8.0 ~12 8~6 ol3 *11~6 6 ~07 5~0 ~13 *11~6 7 ol9 1306 ~13 *11~6 8 ~13 ~3 ~15 4~4 9 ~17 12~2 ~35 *31~1 ' , , , . - ~ ~ :
. . : : . .
., ~ ~ ' . ' ' - ~ :
. .
W09~10227 2 ~ l1 7 7 ~ 2 PCT/usgo/olo28 lo .22 15.8 .13 ~11.6 11 .15 10.8 O07 6.
12 .~8 *29.4 .01 .5 13 .09 ~.5 .02 1.8 14 .51 *31.3 .08 - .41 - .18 12.9 .05 4.4 16 .56 *40.2 .02 1.8 17 .37 *26.5 .03 2.7 18 .50 *35.9 .lO ~.9 19 .40 *2~.7 .04 3.6 .29 20.8 .34 . *30.2 *Positive Results.
The following test according to the protocol in Example 3 was performed on 20 patients having progressive systemic sclerosis. Some anti-cardiolipin antibodies were expected to be present in the samples. Using 23 GPL and 11 MPL as the low positive cut-off number, 4 samples were found positve for IgG
and 1 sample was positive for IgM. The following data was generated by the kest kit:
.. :: . ~,: .................... ; ... . - . . . . -,. .. . , : ., , ~ - . : .
. .. .. .
2~ P~T/US90/01028 PATIENTS ~qG 0.D. GPL IgM O.D. MPL
1 .10 6.7 .07 2.9 2 .09 6.0 .10 4.2 3 .15 10.0 .11 4.6 4 .17 ~1.3 .02 .08 .19 12.7 .03 1.2 6 .41 *27.3 .22 9.2 7 .32 22.7 .10 2.1 8 .34 21.3 .05 2.1 9 .07 4.7 .04 1.7 .10 6.7 .04 1.7 11 o58 *38.7 .35 *14.6 12 .10 6.7 .04 1.7 13 .80 *53.4 .08 3.3 14 .05 3.3 .02 .08 .32 21.3 .14 5.8 16 .17 11.3 .17 7.1 17 .15 10.0 .02 .~
18 .20 14.0 .08 3.3 19 .20 13.3 .09 3.7 .46 *30.7 .11 4.6 * Positive results Example 8 .
~he prevalence of IgG and IgM a-Cl antibodies in a large series of serum samples obtained from 149 systemic lupus erthematosus ~SLE), 93 progressive sclerosis (PSS), 80 .
!
: ' ' .
~,.~ ' , . ~ '.
' . . ~ .
,: ' ' ' . ' ' :~ , , . . ..
... . . . .
W090/~0227 PCT/US90/01028 77 ~ 2 rheumatoid arthritis (RA), 24 osteoarthritis (OA) patients, was tested by the test kit in accordance with the protocol in Example 3. The results were compared to the results from the test kit generated from 202 serum samples obtained from healthy individuals. These patients were followed in rheumatology clinics and the diagnosis of SLE, PSS, and RA was based on ARA criteria. One hundred and two of the healthy individuals were screened and selected by the absence of any clinical manifestation related to the a-CL syndrome, medication, pregnancy or recent infection. The test kit used include controls and calibrators that are standardized against reference samples from EN Harris. The results were expressed as GPL vr MPL units. Each sample was assayed in dup:Licate and the normal ranges were established by the mean value of the unselected healthy individuals + 2 s.d. The prevalence rate is reported as the percent of positive samples above the normal range.
~ean GPLPrevalenceMean MPL Prevalence Serum~/- 1 s.d. GPL (%L +t- 1 s.d. MPL ~
Healthy12 +/- 5.3 2 5 +/- 2.9 4 Healthy7 ~/- 3.0 5 6 ~/- 3.1 4 (selected) SLE*16 -~/-10.8 21 6 ~/- 5.3 10 PSS15 +/-11.0 13 ~ +/- 3.0 3 R~**Zl +/-10.4 42 6 +/- 6.~ S
O~11 +/- 9.7 4 3 ~/- 1.7 0 *No signi~icant correlation between GPL (r = 0.19) or MPL (r =
0.04) with anti-dsDNA was ~ound.
**No signi~icant correlation between GPL (r = 0.01) or MPL (r = 0.09~ with IgM-RF was found.
' ~ . : , ' ' .
.
~a4~ 4~ -42-In this study, the results indicate statistically significant higher serum levels of IgG a-CL antibody activity in patients with SLE (p < 0.00l), PSS (p < 0.025), and RA (p < 0.00l) when compared to healthy individuals and OA patients. The highest prevalence was found in patients with ~ and SLE and this activity cannot be attributed to cross-reactivity ~ith IgM RF
or dsDNA antibodies. There was no statistical difference in IgG or IgM a-CL serum levels in SLE patients with active versus inactive disease. The selection process of the healthy group appears to significantly lower the IgG a-CL mean value (p < 0O00l). IgG a-CL serum levels seem to be the most clinically significant in autoimmune disorders.
The foregoing examples serve to illustrate the efficiency and utility of the methylated BSA to provide a coating which inhibits non-specific binding and provides a coating capable of affixing cardiolipin antigen evenly over the solid support.
Without being bound to the specific quantities given in the definitional section, it is possible to utilize a wide latitude of concentrations of mBSA or other similar, functionally equivalent su~stitutes which have the capability to evenly attach cardiolipin antigen to the support solid by providing a charged surface or by any other like mechanism to affix the cardiolipin and to continue to inhibit non-specific binding.
, WO90/10227 PCT/~S90/01028 ~43~ 2~7742 Likewise, the blocker utilized in the preferred embodiment of this invention to stabilize the shelf life and eliminate non-specific binding cannot be limited to the compounds or the ingredients or the concentrations thereof listed in the definitional section. A variety of functional equivalent blocking agents are known to those skilled in the art. A
partial listing of some materials which could be utilized to perform a similar function is found in (Robert F. Bogt; J.
Immunological Methods, lOl, 43-50 [1987]) and is hereby incorporated herein by reference.
The treatment of the solid support which can be any of a variety of formats, i.e. test tubes, plates, wellsj etc., made of various suitable materials, i.e. glass, plastics, etc., with the aforementioned technology affords many important and useful approaches to the detection of the anti-cardiolipin antibodies. The detection of anti-cardiolipin need not be limited to the conjugation of enzymes. Addition of fluorescent chemicals such as fluorescence or the like to the antibody will impart fluorescence to the assay if the antibody is present. Similarly, conjugation of the antibody with a radionuclide will impart radioactivity to the assay if the antibodies are present in the assay. Many other methods of detection of antibodies also exist, and these methods will yield positive results provided that the antibody exists in the assayed sera and is affixed according to the methods described herein.
'' ~' ' . ~ ' ' ' : . . ' . , ~.
. : , . . ,., , - ~
'~ .: ~ ' ' .', ' ,': ' WO90/lOZ27 PCT/US9OfO10~8 ~ -44-The test kit and the underlying coating and detection methods herebefore describ~d are not intended to be limited by the assay format described or by the volumes or the concentrations or specific ingredients given for the various reagents, controls, and calibrators. It should be understood that similar chemical equivalents or other functional equivalents of the components found in the coatings, or in any of the various reagents, controls, and calibrators can be utilized within the scope of this invention.
It is contemplated that the inventive concepts herein described may have differing embodiments and it is intended that ths appended claims be construed to include all such alternative embodiments of the invention except insofar as they are limited by the prior art.
. .
, .. ~ - . .~ . ,,, ., :
D~T~C~IO~ 0~ C~RDIO~IPI~ IgG
SOUEC~ GPL OD
Cali~rator l 6 .08 Calibrator 2 l8 .17 ~ 26-Calibrator 3 35 .29 Calibrator 4 70 .52 Calibrator 5 105 .68 Refer to Figure 1 Source Mean Value GPL OD
Normal Serum < 2 .05 (positive) anti CL 46 moderate positive plasma .36 antibody plasma RPR positive plasma 45 .42 DETECTION OF CARDIOLIPIN IgM
Source MPL OD
Calibrator l 5 .08 Calibrator 2 l0 .ll Calibrator 3 20 .2 Calibrator 4 50 .45 Calibrator 5 l00 .73 Refer to Figure 2 Source Mean Value MPL OD
Normal Serum < 3 .03 (positive) anti CL 80 high positive plasma .85 antibody plasma RPR positive patient 59 .55 In each test sample, IgG and IgM aCL levels are reported in GPL and MPL units respectively. One GPL unit is defined as the cardiolipin binding activity of l ug/ml of an affinity purified Ig& aCL preparations from a standard serum. one MPL
unit is defined as the cardiolipin binding activity of 1 ug/ml of an affinity purified IgM aCL preparation from a standard serum. The unit~ have been established by Dr. Nigel Harris.
SUBS~Tl~ 1E $HEET
.
~ : : . . .
2~47742 ~XAMPLE 1'~0 To demonstrate the importance of the cardiolipin coating, a polystyrene well was uncoated and the test was run under the procedure described in Example 1. After the wells were assayed with horseradish peroxidase conjugated antibodies, there was only a slight selectivity observed, and a very high background was observed, in contrast to the background and selectivity of the coated wells.
Uncoated Calibrator~MPL Coated Well~ O.D. Wells O D.
lO0 MPL .85 .72 50 MPL .50 ~4 20 MPL .20 .19 10 MPL .12 .13 5 MPL .07 .lO
Uncoated Calibrator~GPL Co~ted ~ells O.D. Well~ O.D.
105 GPL .93 .85 70 GPL .76 .76 18 GPL .28 .36 6 GPL .13 .29 Uncoated ~ourGe~PL Co~tea Well~ O.D. Wells O.D.
~ 7 Normal Serum.04 ,09 Positive #1 .65 .50 Positiva #21.1} .~
WO90/~0227 PCT/US90/01028 t~ 4~
Vncoated 8Ource GPL ~oated_Well~ O.D. Wells O.~.
Normal Serum .0~ .25 Positive #1 .63 .39 Positive #2 .53 .44 EXANPLE THREE
Test Performed with the Diagnostic Test Kit The kit contained 96 pre-coated microwells with affinity for anti-cardiolipin and:
:.
1 vial of (30ml) Sample Diluent (green solution) - containing 0.1~ sodium azide, to be used for diluting sera samples, calibrators and controls.
1 vial of (0.25 ml) Human Negative Control.
2 vials of (0.25 ml) Human GPL Positive Control (two moderate positive controls.
2 vials of (Q.25) ml Human MPL Positive Control (moderate positive control and high positive control).
5 vials of (0.25 ml) calibrators for GPL.
5 vials of (0.25 ml) calibrators ~or MPL.
- , , . :
': ' ' . : ' , -29- 20~77~2 l vial of (8 ml) Conjugated Antibody Working Soluti4n containing horseradish peroxidase con-jugated anti-human IgM; and a second similar vial of (8 ml) Conjugated Antibody Working solution containing horseradish peroxidase conjugated anti-human IgG.
One bottle of (8 ml) of TMB Substrate solution A containing 3,3',5,5', temtramethylbenzidine, and one (8 ml) bottle of Peroxidase Substrate Solution B containing hydrogen peroxide. Solution A and B are combined to form a substrate capable of generating a colored product.
l bottle of (12 ml) Stop Reagent containing 2.5N H2SO4; ~lN
HCl may also be substituted);
A packet of Phosphate Buffered Saline ~PBS). This reconstitutes to 2 liters of 0.0l M PBS, pH 7.4.
l packet of Phosphate Buffered Saline (PBS) which reconstitutes to 2 lit~rs of 0.0l M PBS, pH 7.3, which is utilized as a wash.
l Plate template.
The plate template was labelled for sample placement in the microwells. A 1:50 dilution of the controls, calibrators and patient samples were prepared in sample diluent (green .. , . . .. - , , WO90/10227 PCT/U~9~/01028 2~7~ ~
solution). 10 ul of sample was added to 500 ul sample diluent in a one volume to 50 volume sample dilution.
100 ul of each diluted sample, control or calibrator was added to appropriate microwells. The plate was allowed to incubate for 15 minutes at room temperature. To perform the rinse step the contents of the PBS packet was added to 2 liters of reagent grade water, and the solution was mixed well, until all the crystals were dissolved. Then the buffer was used to wash the wells four times. The microwells were inverted between each wash to empty the fluid, and the wells were blotted on absorbent paper to remove residual wash fluid. Per the klt instructions, the wells were not allowed to dry-out between washes.
100 ul of conjugated antibody (red solution) was added to each well, incubated 15 minutes at room temperature, and then the wells were again washed four times with PBS solution. Next, the wells were blotted on absorbent paper to remove residual wash fluid.
The working substrate was prepared ~ust before using according to the kit instruction. Equal volumes of TMB Su~strate solution A and TMB Substrate Solution B were combined to form the color generating substrate. The kit instructed that if properly combined this substrate solution would be colorless and it was colorless. 100 ul of working substrate solution , .
WO90/1~227 PCT/US90/01028 2~77~2 was added to each well and the wells were incubated for ten minutes at room temperature.
Next 100 ul stop reagent was added to each well to end the enzyme reaction and the O.D. of aach well was read at ~50 nm against a water blank. The results were then calculated by plotting GPL or MPL calibrator values against O.D.s on linear graph paper. Sample results are read from the resulting "standard curve".
Normal Ranqes and Deqree of Positivity:
The following estimates have been established by Dr. Nigel Harris:
Normal = < 5 GPL and ~ 3 MPL
Low Positive = ~ 15 GPL and < 6 MPL
Mod Positive = 15-100 GPL and 6-60 MPL
High Positive = > 100 GPL and > 60 MPL
DETECTION OF CARDIOIIPIN IgG and IgM
Refer to Figures 3 and 4 Control results fell within predetermined ranges.
Mean Mean Controls Value ~PL O~D. ValuQ MPL OoD~
Normal 2 .7 2 .02 ~oderate positive ~6 .76 16 .32 Moderate positive 78 .99 81 .~6 High positive 78 .99 81 o96 SlJBS~lT~T~ SHE~
WO 90/10227 PCr/US90/01028 ~ean ~ean ~;our~e Value GPL O . D, alus MPL O . D.
Normal human serum 3 . 08 2 . 02 aCL ~high positive) 92 1.15 70 . 87 aCL (moderate positive) 44 . 73 17 . 34 :
, ~
.
W09OtlO227 PCT/U~90/01028 ~33~ 2 0~77 ~2 EXAMP~B 4 Samples wexe drawn from 52 patients that tested VDRL positive.
The test was run in accordance with Example 3. Approximately 17% of the samples showed positive for anti-Cardiolipin antbodies. The low positive IgG was determined to be 23 GPL, and the low positive IgM was determined to be 11 MPL. After converting the O.D. data, the following values were obtained:
Patient GPL MPL
1 5.5 4.7 2 7.~ 1.3 3 23.1 6.7 4 2.9 6.7 16.0 8.0 6 9.3 3.3 7 65.2 .6.0 8 6.5 3.3 9 39.9 12.7 9.3 7.3 11 7.8 10.7 12 4.6 4.7 13 18.3 12.0 14 12.9 2.0 28.5 6.0 16 13.2 16.0 17 14.8 4.0 18 12.6 6.7 19 9.5 4.0 6.8 7.3 21 10.3 2.7 22 3.3 2.7 23 4.1 4.0 24 7.7 6.0 5.5 5.3 26 19.9 8.0 27 7.1 1.7 28 8.7 5.8 29 7.7 5.0 4.2 2.9 31 15.5 10.8 32 ~.1 6.7 33 13.4 9.6 34 7.4 4.2 3.7 ~.3 36 31.6 6.7 ... , ~ .
.
, . ; . : .
: ,. ;,:
W~ 90/10227, P~/US90/~102 --3~
37 13.0 1.7 38 9.2 4.6 39 5.7 2.5 4.8 2.1 41 7.1 5.0 42 2.5 2.1 43 18.7 7.9 44 48 . 2 30 . O
8.~ 1.7 46 ~7.5 ~;.7 47 15.3 3.3 48 5.2 1.7 49 6.4 1.7 11.8 6.7 51 2.7 8.3 52 8.5 1.3 .
''~' , ' ' ' ~:
, ~.
.
WO90/10~27 PCT/~S90/01028 -~5-2~7~2 The following test was run according to the protocol outlined in Example 3. The samples were taken ~rom patients known to have rheumatoid arthritis, thus some anti-cardiolipin antibodies are expected to be present. A low positive was determined to be 23 GPL and 11 MPL base~ on the calibrators used. There were approximately 42% positive for IgG anti-cardiolipin antibodies and 6% positive for IgM anti-cardiolipin antibodies. The following data was generated using the present invention.
Patient Iq~ O.D. GPL IaM O.D. MPL
1 .10 6.6 .0~ 3.1 2 .28 18.3 .12 4.7 3 .44 ~28.~ .16 6.2 4 .46 *30.1 .11 4.3 .52 *34.1 .18 7.0 6 .46 *~0.1 .19 7.4 7 .51 *33.4 .16 6.2 8 .12 7.9 .10 3.9 9 .12 7.9 .08 3.1 .68 *44.5 .18 7.0 11 .20 13.1 .09 3.5 12 .13 8.5 .10 3.9 13 .20 13.1 .013 S.1 14 .31 20.3 .48 18.7 .12 7.9 .16 ~.2 16 .15 ~.~ .11 4.3 .
: ' . . , . ' ~ : ' - ~ . , . "
'': ' ' .': : . ' : ' - '' ' ~ , .: ~ : : : . ::
WO90/10227 ~ 36- PCT/US90/010~8 17 .15 9.8 .04 1.6 18 .18 11.8 .20 7.8 19 .60 *39.3 1.21 *47.2 .36 *23.6 .17 6.6 21 .22 14.4 .11 4.3 22 .38 *24.9 .12 4.7 23 .4~ *32.1 .1~ 6.2 24 .21 13.8 .07 2.7 .30 19.7 .06 2.3 26 .023 15.1 .1~ 6.2 27 .21 13.8 .21 8.2 28 .19 12.4 .10 3.9 29 .15 9.8 .16 6.2 .31 20.3 .86 33.5 31 .20 13.1 .08 3.1 32 .15 9.8 .07 2.7 33 .30 19.7 .09 3.5 34 .56 *36.7 .12 4.7 .20 14.4 .12 4.7 36 .2~3 18.3 .11 4~3 37 .32 20.1 .14 5.5 38 .56 *36.7 .07 2.7 39 .28 18.3 .11 4.3 .27 17.7 .11 4.3 41 ~41 *30~0 ol2 5~1 4~ .34 *24.9 .5 ~21.1 43 .30 21.9 .~2 5.1 44 .41 *30.0 .12 5.1 . ` ' ' , ' '' ' ' ~- ~ .. ' , - . ~ .':
. ; . .
WO90/10~27 P~TIU~90101028 _37_ 2~77~2 .32 *23.4 .09 3.8 46 .32 *23.4 .10 4.2 47 .33 *24.1 .20 8.4 48 .54 *39.5 .14 5.9 49 .21 15.4 .12 5.1 .32 *23.4 .17 7.2 51 .46 *33.6 .08 3.4 52 .23 16.8 .07 2.9 53 .05 3.7 .02 .8 54 .64 *46.8 .20 8.4 .44 *32.2 .07 2.g 56 .23 16.8 .11 4.6 57 .14 10.2 .12 5.1 58 .22 16.1 .09 3.8 59 .34 *24.9 .07 2.9 .61 *44.6 .12 5.1 61 .32 *23.4 .12 ~1 62 .51 *37.3 .09 3.8 63 .12 8.8 .10 4.2 64 .30 2~.9 .10 4.2 .34 *24.g .18 7.6 66 .37 *27.0 .10 4.2 67 .42 *30.7 .12 5.1 ~8 .~5 *40.2 .19 8.0 69 .15 11.0 .10 4.2 .36 *26.3 .39 1~.4 71 .~8 13.2 .16 6.7 72 .20 14.6 .16 6.7 ' ~ ' ' ' ''' . .:
WO90/tO227 PCT/US90/01028 ~ -38-73 ` .06 4.4 .17 7.2 74 .30 21.9 .13 5.5 .48 *35.1 .10 4.2 76 .35 *25.6 .08 3.4 77 .22 16,1 .07 2.9 78 .15 11.0 .14 5.9 79 .21 15.4 .13 5.5 .16 11.7 .18 7.6 *Positive Results.
The following test was run according to the pro~ocol outlined in Example 3. The samples were suspected of hav:ing anti-cardiolipin antibodies as the patients were all SLE patients.
The low positive was determined to be 23 GPL and 11 MPL. Seven patients were GPL positive and seven were MPL positive. The followin~ data was gathered by the test kit procedure:
PATIENT IqG O D. GPL IaM O.D. MPL
1 O43 *26.4 .20 10.2 2 .11 7.9 .14 *12.4 3 .25 17.9 .04 3.6 4 .10 7.2 .0~ 8.0 ~12 8~6 ol3 *11~6 6 ~07 5~0 ~13 *11~6 7 ol9 1306 ~13 *11~6 8 ~13 ~3 ~15 4~4 9 ~17 12~2 ~35 *31~1 ' , , , . - ~ ~ :
. . : : . .
., ~ ~ ' . ' ' - ~ :
. .
W09~10227 2 ~ l1 7 7 ~ 2 PCT/usgo/olo28 lo .22 15.8 .13 ~11.6 11 .15 10.8 O07 6.
12 .~8 *29.4 .01 .5 13 .09 ~.5 .02 1.8 14 .51 *31.3 .08 - .41 - .18 12.9 .05 4.4 16 .56 *40.2 .02 1.8 17 .37 *26.5 .03 2.7 18 .50 *35.9 .lO ~.9 19 .40 *2~.7 .04 3.6 .29 20.8 .34 . *30.2 *Positive Results.
The following test according to the protocol in Example 3 was performed on 20 patients having progressive systemic sclerosis. Some anti-cardiolipin antibodies were expected to be present in the samples. Using 23 GPL and 11 MPL as the low positive cut-off number, 4 samples were found positve for IgG
and 1 sample was positive for IgM. The following data was generated by the kest kit:
.. :: . ~,: .................... ; ... . - . . . . -,. .. . , : ., , ~ - . : .
. .. .. .
2~ P~T/US90/01028 PATIENTS ~qG 0.D. GPL IgM O.D. MPL
1 .10 6.7 .07 2.9 2 .09 6.0 .10 4.2 3 .15 10.0 .11 4.6 4 .17 ~1.3 .02 .08 .19 12.7 .03 1.2 6 .41 *27.3 .22 9.2 7 .32 22.7 .10 2.1 8 .34 21.3 .05 2.1 9 .07 4.7 .04 1.7 .10 6.7 .04 1.7 11 o58 *38.7 .35 *14.6 12 .10 6.7 .04 1.7 13 .80 *53.4 .08 3.3 14 .05 3.3 .02 .08 .32 21.3 .14 5.8 16 .17 11.3 .17 7.1 17 .15 10.0 .02 .~
18 .20 14.0 .08 3.3 19 .20 13.3 .09 3.7 .46 *30.7 .11 4.6 * Positive results Example 8 .
~he prevalence of IgG and IgM a-Cl antibodies in a large series of serum samples obtained from 149 systemic lupus erthematosus ~SLE), 93 progressive sclerosis (PSS), 80 .
!
: ' ' .
~,.~ ' , . ~ '.
' . . ~ .
,: ' ' ' . ' ' :~ , , . . ..
... . . . .
W090/~0227 PCT/US90/01028 77 ~ 2 rheumatoid arthritis (RA), 24 osteoarthritis (OA) patients, was tested by the test kit in accordance with the protocol in Example 3. The results were compared to the results from the test kit generated from 202 serum samples obtained from healthy individuals. These patients were followed in rheumatology clinics and the diagnosis of SLE, PSS, and RA was based on ARA criteria. One hundred and two of the healthy individuals were screened and selected by the absence of any clinical manifestation related to the a-CL syndrome, medication, pregnancy or recent infection. The test kit used include controls and calibrators that are standardized against reference samples from EN Harris. The results were expressed as GPL vr MPL units. Each sample was assayed in dup:Licate and the normal ranges were established by the mean value of the unselected healthy individuals + 2 s.d. The prevalence rate is reported as the percent of positive samples above the normal range.
~ean GPLPrevalenceMean MPL Prevalence Serum~/- 1 s.d. GPL (%L +t- 1 s.d. MPL ~
Healthy12 +/- 5.3 2 5 +/- 2.9 4 Healthy7 ~/- 3.0 5 6 ~/- 3.1 4 (selected) SLE*16 -~/-10.8 21 6 ~/- 5.3 10 PSS15 +/-11.0 13 ~ +/- 3.0 3 R~**Zl +/-10.4 42 6 +/- 6.~ S
O~11 +/- 9.7 4 3 ~/- 1.7 0 *No signi~icant correlation between GPL (r = 0.19) or MPL (r =
0.04) with anti-dsDNA was ~ound.
**No signi~icant correlation between GPL (r = 0.01) or MPL (r = 0.09~ with IgM-RF was found.
' ~ . : , ' ' .
.
~a4~ 4~ -42-In this study, the results indicate statistically significant higher serum levels of IgG a-CL antibody activity in patients with SLE (p < 0.00l), PSS (p < 0.025), and RA (p < 0.00l) when compared to healthy individuals and OA patients. The highest prevalence was found in patients with ~ and SLE and this activity cannot be attributed to cross-reactivity ~ith IgM RF
or dsDNA antibodies. There was no statistical difference in IgG or IgM a-CL serum levels in SLE patients with active versus inactive disease. The selection process of the healthy group appears to significantly lower the IgG a-CL mean value (p < 0O00l). IgG a-CL serum levels seem to be the most clinically significant in autoimmune disorders.
The foregoing examples serve to illustrate the efficiency and utility of the methylated BSA to provide a coating which inhibits non-specific binding and provides a coating capable of affixing cardiolipin antigen evenly over the solid support.
Without being bound to the specific quantities given in the definitional section, it is possible to utilize a wide latitude of concentrations of mBSA or other similar, functionally equivalent su~stitutes which have the capability to evenly attach cardiolipin antigen to the support solid by providing a charged surface or by any other like mechanism to affix the cardiolipin and to continue to inhibit non-specific binding.
, WO90/10227 PCT/~S90/01028 ~43~ 2~7742 Likewise, the blocker utilized in the preferred embodiment of this invention to stabilize the shelf life and eliminate non-specific binding cannot be limited to the compounds or the ingredients or the concentrations thereof listed in the definitional section. A variety of functional equivalent blocking agents are known to those skilled in the art. A
partial listing of some materials which could be utilized to perform a similar function is found in (Robert F. Bogt; J.
Immunological Methods, lOl, 43-50 [1987]) and is hereby incorporated herein by reference.
The treatment of the solid support which can be any of a variety of formats, i.e. test tubes, plates, wellsj etc., made of various suitable materials, i.e. glass, plastics, etc., with the aforementioned technology affords many important and useful approaches to the detection of the anti-cardiolipin antibodies. The detection of anti-cardiolipin need not be limited to the conjugation of enzymes. Addition of fluorescent chemicals such as fluorescence or the like to the antibody will impart fluorescence to the assay if the antibody is present. Similarly, conjugation of the antibody with a radionuclide will impart radioactivity to the assay if the antibodies are present in the assay. Many other methods of detection of antibodies also exist, and these methods will yield positive results provided that the antibody exists in the assayed sera and is affixed according to the methods described herein.
'' ~' ' . ~ ' ' ' : . . ' . , ~.
. : , . . ,., , - ~
'~ .: ~ ' ' .', ' ,': ' WO90/lOZ27 PCT/US9OfO10~8 ~ -44-The test kit and the underlying coating and detection methods herebefore describ~d are not intended to be limited by the assay format described or by the volumes or the concentrations or specific ingredients given for the various reagents, controls, and calibrators. It should be understood that similar chemical equivalents or other functional equivalents of the components found in the coatings, or in any of the various reagents, controls, and calibrators can be utilized within the scope of this invention.
It is contemplated that the inventive concepts herein described may have differing embodiments and it is intended that ths appended claims be construed to include all such alternative embodiments of the invention except insofar as they are limited by the prior art.
. .
, .. ~ - . .~ . ,,, ., :
Claims (3)
1. A solid article for selectively detecting anti-cardiolipin antibodies from solutions placed in contact with such article comprising:
* support means adapted to be contacted with solutions containing anti-cardiolipins;
* coating means comprising a composition containing methylated BSA capable of being affixed to said support;
* a coating means comprising a composition containing cardiolipin ligand capable of adhering anti-cardiolipin antibodies; and * a blocking means capable of limiting non-specific binding to the solid support; whereby the coated solid article is capable of adhering any anti-cardiolipins exposed to the coating.
* support means adapted to be contacted with solutions containing anti-cardiolipins;
* coating means comprising a composition containing methylated BSA capable of being affixed to said support;
* a coating means comprising a composition containing cardiolipin ligand capable of adhering anti-cardiolipin antibodies; and * a blocking means capable of limiting non-specific binding to the solid support; whereby the coated solid article is capable of adhering any anti-cardiolipins exposed to the coating.
2. A method of performing an assay for anti-cardiolipin antibodies in serum comprising the steps of contacting the coated support article with a solution to be tested for the presence of anti-cardiolipin; facilitating adherence of the anti-cardiolipin present in the solution to the coating on the solid article; and detecting the anti-cardiolipin retained by said coating.
3. A diagnostic test kit comprised of a solid article for selectively detecting anti-cardiolipin antibodies from solutions placed in contact with such article comprising:
* support means adapted to be contacted with solutions containing anti-cardiolipins;
* coating means comprising a composition containing methylated BSA capable of being affixed to said support;
* a coating means comprising a composition containing cardiolipin ligand capable of adhering anti-cardiolipin antibodies; and * a blocking means capable of limiting non-specific binding to the solid support; whereby the coated solid article is capable of adhering any anti-cardiolipins exposed to the coating;
and utilizing a method of performing an assay for anti-cardiolipin antibodies in serum comprising the steps of contacting the coated support article with a solution to be tested for the presence of anti-cardiolipin; facilitating adherence of the anti-cardiolipin present in the solution to the coating on the solid article; and detecting the anti-cardiolipin retained by said coating.
* support means adapted to be contacted with solutions containing anti-cardiolipins;
* coating means comprising a composition containing methylated BSA capable of being affixed to said support;
* a coating means comprising a composition containing cardiolipin ligand capable of adhering anti-cardiolipin antibodies; and * a blocking means capable of limiting non-specific binding to the solid support; whereby the coated solid article is capable of adhering any anti-cardiolipins exposed to the coating;
and utilizing a method of performing an assay for anti-cardiolipin antibodies in serum comprising the steps of contacting the coated support article with a solution to be tested for the presence of anti-cardiolipin; facilitating adherence of the anti-cardiolipin present in the solution to the coating on the solid article; and detecting the anti-cardiolipin retained by said coating.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31556689A | 1989-02-27 | 1989-02-27 | |
US315,566 | 1989-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2047742A1 true CA2047742A1 (en) | 1990-08-28 |
Family
ID=23225025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002047742A Abandoned CA2047742A1 (en) | 1989-02-27 | 1990-02-26 | Method and diagnostic test kit for detection of anti-cardiolipin |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0460097A4 (en) |
AU (1) | AU5262390A (en) |
CA (1) | CA2047742A1 (en) |
WO (1) | WO1990010227A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990010229A1 (en) * | 1989-02-27 | 1990-09-07 | Biostar Medical Products, Inc. | Method and diagnostic test kit for detection of autoimmune antibody |
ATE142789T1 (en) * | 1989-10-19 | 1996-09-15 | Yamasa Shoyu Kk | CARRIER FOR BINDING ANTIPHOSPHOLIPIDE ANTIBODIES, IMMUNO TEST USING THESE ANTIBODIES AND KIT THEREOF |
AU644163B2 (en) * | 1990-04-06 | 1993-12-02 | Yamasa Shoyu Co. Ltd. | Methods for determining phospholipids and antibodies thereof |
US6177282B1 (en) | 1997-08-12 | 2001-01-23 | Mcintyre John A. | Antigens embedded in thermoplastic |
US8778619B2 (en) | 2005-11-18 | 2014-07-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oxidized cardiolipin and uses to detect cardiolipin antibodies |
EP1949108B1 (en) * | 2005-11-18 | 2013-09-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Modified cardiolipin and uses therefor |
CN103185785B (en) * | 2011-12-30 | 2015-01-07 | 深圳市亚辉龙生物科技有限公司 | Reagent device and method for detecting anti-cardiolipin antibody |
CN103185783B (en) * | 2011-12-30 | 2015-01-07 | 深圳市亚辉龙生物科技有限公司 | Reagent device and method for detecting anti-SSB antibody |
CN117288948B (en) * | 2023-06-19 | 2024-06-04 | 无锡嘉润诊断技术有限公司 | Anti-prothrombin antibody detection kit |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4738932A (en) * | 1985-12-03 | 1988-04-19 | Advanced Polymer Systems, Inc. | Reaginic test for syphilis |
-
1990
- 1990-02-26 WO PCT/US1990/001028 patent/WO1990010227A1/en not_active Application Discontinuation
- 1990-02-26 CA CA002047742A patent/CA2047742A1/en not_active Abandoned
- 1990-02-26 AU AU52623/90A patent/AU5262390A/en not_active Abandoned
- 1990-02-26 EP EP19900904518 patent/EP0460097A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1990010227A1 (en) | 1990-09-07 |
EP0460097A1 (en) | 1991-12-11 |
AU5262390A (en) | 1990-09-26 |
EP0460097A4 (en) | 1992-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4016043A (en) | Enzymatic immunological method for the determination of antigens and antibodies | |
US4020151A (en) | Method for quantitation of antigens or antibodies on a solid surface | |
AU720123B2 (en) | Antigen-specific IgM detection | |
JP3330604B2 (en) | Solid-phase immunoassay | |
EP0124352A2 (en) | Protected binding assay | |
JP2636331B2 (en) | One-step assay for antigen-specific antibodies and suitable reagents | |
CA1256025A (en) | Immuno-chemical measurement process for haptens and proteins | |
US4267270A (en) | Method for the determination of antigens and antibodies using site-deactivating media | |
US5814461A (en) | Method for the determination of anti-TSH receptor autoantibodies | |
EP0345277B1 (en) | Analyte detection in particulate-containing samples | |
EP0350233B1 (en) | An article for performing immunological assays utilizing organic dyes and methods for producing and utilizing same | |
CA2047742A1 (en) | Method and diagnostic test kit for detection of anti-cardiolipin | |
JPH09504374A (en) | Immunoassay for detecting human autoantibodies | |
JP2002277464A (en) | Improved binding assay | |
JP2553852B2 (en) | Immunological assay for biological substances in samples | |
CA2001253C (en) | Process for the determination of antibodies which are class-specific for an antigen and a reagent for carrying out the process | |
US5183735A (en) | Method and diagnostic test kit for detection of anti-dsDNA antibodies | |
EP0460102A1 (en) | Method and diagnostic test kit for detection of autoimmune antibody | |
WO1990015328A1 (en) | Improved immunoassay | |
CN106596524A (en) | Chemiluminescence immunoassay kit for insulin antibodies and preparation method of kit | |
US4391795A (en) | Assay for free thyroid hormone | |
USRE32696E (en) | Enzymatic immunological method for determination of antigens and antibodies | |
Murthy et al. | Activity concentration and mass concentration (monoclonal antibody immunoenzymometric method) compared for creatine kinase MB isoenzyme in serum. | |
EP0080108B1 (en) | Diagnostic reagent and use thereof | |
US5277589A (en) | Process for the determination of antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |